Search Result

Results for "

autoimmune

" in MCE Product Catalog:

By Targets:	5-HT Receptor (1) ADC Linker (1) Adenosine Receptor (1) Adrenergic Receptor (1) AIM2 (1) Akt (1) Aldehyde Dehydrogenase (ALDH) (1) Aminopeptidase (1) AMPK (1) Amyloid-β (1) Antibiotic (1) Apoptosis (11) Arenavirus (2) Arginase (1) Autophagy (5) Bacterial (1) Biochemical Assay Reagents (2) Btk (15) c-Fms (1) Caspase (1) CCR (4) CD20 (2) CD22 (1) CD28 (1) CDK (1) Cholinesterase (ChE) (1) Complement System (5) COX (1) CRAC Channel (1) CTLA-4 (1) CXCR (2) DAPK (1) Dihydroorotate Dehydrogenase (2) DNA Alkylator/Crosslinker (2) Drug Metabolite (3) Drug-Linker Conjugates for ADC (1) EBI2/GPR183 (1) Endogenous Metabolite (3) Epigenetic Reader Domain (2) Estrogen Receptor/ERR (1) Fungal (1) FXR (2) Glucocorticoid Receptor (2) GLUT (1) Glutaminase (1) HCV Protease (1) Histamine Receptor (5) Histone Acetyltransferase (1) Histone Methyltransferase (3) IFNAR (1) IKK (1) Indoleamine 2,3-Dioxygenase (IDO) (3) Influenza Virus (6) Integrin (3) Interleukin Related (17) IRAK (5) JAK (22) LDLR (1) Lipoxygenase (1) LPL Receptor (14) LRRK2 (1) MALT1 (1) Melatonin Receptor (1) Monoamine Oxidase (2) Na+/K+ ATPase (1) Necroptosis (1) NF-κB (3) NO Synthase (1) NOD-like Receptor (NLR) (1) Notch (1) Nuclear Factor of activated T Cells (NFAT) (1) p38 MAPK (3) Parasite (4) PD-1/PD-L1 (4) Phosphatase (2) Phosphodiesterase (PDE) (1) Phospholipase (2) PI3K (4) PKC (2) Potassium Channel (3) Prostaglandin Receptor (1) PROTACs (1) Proteasome (4) Protein Arginine Deiminase (3) Pyruvate Kinase (1) Reactive Oxygen Species (2) RET (1) REV-ERB (1) RIP kinase (1) ROR (11) Salt-inducible Kinase (SIK) (1) SARS-CoV (2) SHP2 (1) STAT (1) STING (1) Syk (2) TAM Receptor (4) TGF-β Receptor (2) TNF Receptor (8) Toll-like Receptor (TLR) (8) TRP Channel (1) Tyrosinase (1) VD/VDR (1) γ-secretase (2)
By Research Areas:	Cancer (70) Cardiovascular Disease (12) Endocrinology (3) Infection (18) Inflammation/Immunology (233) Metabolic Disease (16) Neurological Disease (24)

By Targets:

5-HT Receptor (1)

ADC Linker (1)

Adenosine Receptor (1)

Adrenergic Receptor (1)

AIM2 (1)

Akt (1)

Aldehyde Dehydrogenase (ALDH) (1)

Aminopeptidase (1)

AMPK (1)

Amyloid-β (1)

Antibiotic (1)

Apoptosis (11)

Arenavirus (2)

Arginase (1)

Autophagy (5)

Bacterial (1)

Biochemical Assay Reagents (2)

Btk (15)

c-Fms (1)

Caspase (1)

CCR (4)

CD20 (2)

CD22 (1)

CD28 (1)

CDK (1)

Cholinesterase (ChE) (1)

Complement System (5)

COX (1)

CRAC Channel (1)

CTLA-4 (1)

CXCR (2)

DAPK (1)

Dihydroorotate Dehydrogenase (2)

DNA Alkylator/Crosslinker (2)

Drug Metabolite (3)

Drug-Linker Conjugates for ADC (1)

EBI2/GPR183 (1)

Endogenous Metabolite (3)

Epigenetic Reader Domain (2)

Estrogen Receptor/ERR (1)

Fungal (1)

FXR (2)

Glucocorticoid Receptor (2)

GLUT (1)

Glutaminase (1)

HCV Protease (1)

Histamine Receptor (5)

Histone Acetyltransferase (1)

Histone Methyltransferase (3)

IFNAR (1)

IKK (1)

Indoleamine 2,3-Dioxygenase (IDO) (3)

Influenza Virus (6)

Integrin (3)

Interleukin Related (17)

IRAK (5)

JAK (22)

LDLR (1)

Lipoxygenase (1)

LPL Receptor (14)

LRRK2 (1)

MALT1 (1)

Melatonin Receptor (1)

Monoamine Oxidase (2)

Na+/K+ ATPase (1)

Necroptosis (1)

NF-κB (3)

NO Synthase (1)

NOD-like Receptor (NLR) (1)

Notch (1)

Nuclear Factor of activated T Cells (NFAT) (1)

p38 MAPK (3)

Parasite (4)

PD-1/PD-L1 (4)

Phosphatase (2)

Phosphodiesterase (PDE) (1)

Phospholipase (2)

PI3K (4)

PKC (2)

Potassium Channel (3)

Prostaglandin Receptor (1)

PROTACs (1)

Proteasome (4)

Protein Arginine Deiminase (3)

Pyruvate Kinase (1)

Reactive Oxygen Species (2)

RET (1)

REV-ERB (1)

RIP kinase (1)

ROR (11)

Salt-inducible Kinase (SIK) (1)

SARS-CoV (2)

SHP2 (1)

STAT (1)

STING (1)

Syk (2)

TAM Receptor (4)

TGF-β Receptor (2)

TNF Receptor (8)

Toll-like Receptor (TLR) (8)

TRP Channel (1)

Tyrosinase (1)

VD/VDR (1)

γ-secretase (2)

By Research Areas:

Cancer (70)

Cardiovascular Disease (12)

Endocrinology (3)

Infection (18)

Inflammation/Immunology (233)

Metabolic Disease (16)

Neurological Disease (24)

230

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas

HY-B1084

Cinoctramide
Others Others

Cinoctramide is an intermediate of pharmaceutical synthesis. Cinoctramide can be used for the research of autoimmune diseases.

Cinoctramide	Others	Others
Cinoctramide is an intermediate of pharmaceutical synthesis. Cinoctramide can be used for the research of autoimmune diseases.

HY-119245

Udifitimod BMS-986166	LPL Receptor	Inflammation/Immunology
Udifitimod (BMS-986166) is a potent, selective and orally active S1P1R modulator. Udifitimod has the potential for the research of autoimmune diseases.

HY-N3103

p-Coumaric Acid Ethyl Ester Ethyl (E)-p-hydroxycinnamate; Ethyl trans-4-hydroxycinnamate	Drug Metabolite	Inflammation/Immunology
p-Coumaric Acid Ethyl Ester is the ethyl ester of p-Coumaric acid. p-Coumaric Acid is a potential immunosuppressive agent in treating autoimmune inflammatory diseases like rheumatoid arthritis.

HY-139203

IL-17 modulator 3	Interleukin Related	Cancer Inflammation/Immunology
IL-17 modulator 3 is an IL-17 modulator (US20200247785A1). IL-17 modulator 3 can be used for the research of inflammation, cancer and autoimmune diseases.

HY-147021A

MC-D-Val-Cit-PAB-PNP	ADC Linker	Cancer Infection Inflammation/Immunology
MC-D-Val-Cit-PAB-PNP is a agent-linker-ligand conjugates. MC-D-Val-Cit-PAB-PNP can be used for researching cancer, autoimmune diseases and infectious diseases.

HY-143480

RIPK1-IN-15	RIP kinase	Inflammation/Immunology Neurological Disease
RIPK1-IN-15 (Compound 2.5) is a potent inhibitor of RIPK1. RIPK1-IN-15 has the potential for the research neurodegenerative, autoimmune, and inflammatory diseases.

HY-144619

TLR7/8 antagonist 2	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7/8 antagonist 2 (Compound 15) is a potent and orally active agonist of TLR7/8 with IC₅₀s of 4.9 and 0.6 nM, respectively. Inappropriate activation of TLR7 and TLR8 is linked to several autoimmune diseases, such as lupus erythematosus. TLR7/8 antagonist 2 has the potential for the research of autoimmune diseases.

HY-20457

TL8-506	Toll-like Receptor (TLR)	Inflammation/Immunology
TL8-506 is a specific TLR8 agonist with an EC₅₀ of 30 nM. TL8-506 can be used for the research of tuberculosis and autoimmune diseases.

HY-12336

NIBR189	EBI2/GPR183	Inflammation/Immunology
NIBR189 is an EBI2 (Epstein-Barr virus-induced gene 2) antagonist. NIBR189 inhibits human and mouse EBI2 with IC₅₀s of 11 and 16 nM, respectively. NIBR189 can be used for the research of autoimmune diseases.

HY-137553

β-Aminoarteether SM934 free base	NOD-like Receptor (NLR)	Inflammation/Immunology
β-Aminoarteether (SM934 free base) is an Artemisinin derivative with orally active. β-Aminoarteether can be used for inflammation and autoimmune disease research, such as lupus diseases.

HY-142940

RORγt modulator 5	ROR	Inflammation/Immunology
RORγt modulator 5 is a RORγt modulator with a K_i value of <100 nM. RORγt modulator 5 has the potential for inflammatory, metabolic, autoimmune and other diseases mediated by RORy study (WO2017132432A1; compound 2).

HY-107560

4-Methylhistamine dihydrochloride	Histamine Receptor	Cancer
4-Methylhistamine (dihydrochloride) is the potent agonist of histamine 4 receptor (H4R). 4-Methylhistamine (dihydrochloride) has the potential for the research of immune-related diseases such as cancer and autoimmune disorders.

HY-150203

GLPG3970	Salt-inducible Kinase (SIK)	Inflammation/Immunology
GLPG3970 (compound 88) is a first-in-class SIK2/SIK3 inhibitor. GLPG3970 can be used for the research of inflammation and autoimmune disease.

HY-18166

NIBR0213	LPL Receptor	Inflammation/Immunology
NIBR-0213 is a potent and selective S1P1 antagonist with efficacy in experimental autoimmune encephalomyelitis. NIBR-0213 displays potent and comparable potency on human and rat S1P1 (IC₅₀ of 2.0 nM and 2.3 nM, respectively) in GTPγ³⁵S assays.

HY-144882

(R)-HH2853	Histone Methyltransferase	Cancer Inflammation/Immunology
(R)-HH2853 is a mutant EZH2 inhibitor with an IC₅₀ of <100 nM for EZH2-Y641F. (R)-HH2853 can be used for cancer and autoimmune diseases (WO2018045971A1; compound 201).

HY-142934

RORγt inhibitor 2	ROR	Inflammation/Immunology Cancer
RORγt inhibitor 2 (Compound 119) is a potent RORγt inhibitor with an IC₅₀ of 9.2 nM. RORγt inhibitor 2 can be used for the research of cancer, inflammation or autoimmune diseases mediated by RORγt.

HY-133807A

(Rac)-Benpyrine	TNF Receptor	Inflammation/Immunology
(Rac)-Benpyrine, a racemate of Benpyrine, is a potent and orally active TNF-α inhibitor. (Rac)-Benpyrine has the potential for TNF-α mediated inflammatory and autoimmune disease research.

HY-147374

Bromodomain inhibitor-9	Epigenetic Reader Domain	Metabolic Disease Inflammation/Immunology
Bromodomain inhibitor-9 is a Bromodomains inhibitor that selectively inhibits BRD4-1 (K_d: 12 nM). Bromodomain inhibitor-9 can be used in the research of diseases or conditions associated with systemic or tissue inflammation, lipid metabolism, fibrosis or chronic autoimmune diseases.

HY-150232

MALT1-IN-11	MALT1	Cancer Inflammation/Immunology
MALT1-IN-11 (Example 151 in reference Patent) is a MALT1 protease inhibitor (IC₅₀ < 10 nM). MALT1-IN-11 inhibits IL10 secretion with an IC₅₀ of 10-100 nM. MALT1-IN-11 can be used for the research of cancer, autoimmune and inflammatory disorders.

HY-P99563

Tibulizumab LY 3090106; LY-3090106; LY3090106	TNF Receptor Interleukin Related	Inflammation/Immunology
Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research.

HY-W010144

Phenidone	COX Lipoxygenase	Inflammation/Immunology Cardiovascular Disease
Phenidone, an orally active dual inhibitor of cyclooxygenase (COX) and lipoxygenase (LOX), ameliorates rat paralysis in experimental autoimmune encephalomyelitis. Phenidone is a potent hypotensive agent in the spontaneously hypertensive rat. Phenidone is used as a photographic developer.

HY-145010

SN-011	STING	Inflammation/Immunology
SN-011 is a potent and selective mouse and human STING inhibitor, with an IC₅₀ of 76 nM for STING signaling. SN-011 competes with cyclic dinucleotide (CDN) for the binding pocket of the STING dimer, blocking CDN binding and STING activation. SN-011 can be used for the research of STING-driven autoimmune and inflammatory disease.

HY-149006

CK156	DAPK	Inflammation/Immunology Cancer
CK156 is a highly selective death-associated protein kinase (DAPK) inhibitor with IC₅₀s of 182 nM,34 μM, and 39 μM in the DRAK1 NanoBRET assay for DRAK1, CK2a1, and CK2a2, respectively. CK156 can be used for the research of autoimmune and inflammatory diseases.

HY-145943

MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT	Drug-Linker Conjugates for ADC	Cancer Inflammation/Immunology
MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT is a?agent-linker conjugate for antibody-drug conjugate (ADC). MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT has?the?potential?for?cancer and autoimmune disease?research.

HY-19569

Upadacitinib ABT-494	JAK	Inflammation/Immunology
Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research.

HY-147585

C5aR-IN-1	Complement System	Inflammation/Immunology
C5aR-IN-1 is a potent inhibitor of C5aR. Increased level of C5a has been associated with disorders such as autoimmune disorders and inflammatory disorders. C5aR-IN-1 has the potential for the research of inflammation diseases (extracted from patent WO2022028586A1, compound 47).

HY-147587

C5aR-IN-3	Complement System	Inflammation/Immunology
C5aR-IN-3 is a potent inhibitor of C5aR. Increased level of C5a has been associated with disorders such as autoimmune disorders and inflammatory disorders. C5aR-IN-3 has the potential for the research of inflammation diseases (extracted from patent WO2022028586A1, compound 89).

HY-147586

C5aR-IN-2	Complement System	Inflammation/Immunology
C5aR-IN-2 is a potent inhibitor of C5aR. Increased level of C5a has been associated with disorders such as autoimmune disorders and inflammatory disorders. C5aR-IN-2 has the potential for the research of inflammation diseases (extracted from patent WO2022028586A1, compound 49).

HY-111021

ASP-4058	LPL Receptor	Inflammation/Immunology
ASP-4058 is a next-generation, selective and oral bioactive agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P₁ and S1P₅), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile.

HY-111021A

ASP-4058 hydrochloride	LPL Receptor	Inflammation/Immunology
ASP-4058 hydrochloride is a next-generation, selective and orally active agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P₁ and S1P₅), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile.

HY-145919

hGPR91 antagonist 3	Others	Inflammation/Immunology Cardiovascular Disease
hGPR91 antagonist 3 (Compound 5g) is a potent, selective, and orally active antagonist of hGPR91 (%F: 26). hGPR91 antagonist 3 has the potential for the research of hypertension, autoimmune disease and retinal angiogenesis.

HY-138281

Complement factor D-IN-2	Complement System	Inflammation/Immunology
Complement factor D-IN-2 is an inhibitor of complement factor D extracted from patent WO2015130838A1, compound 190. Complement factor D-IN-2 targets factor D and inhibits the complement cascade at an early and essential point in the alternative complement pathway. Complement factor D-IN-2 can be used for the research of autoimmune diseases.

HY-144032

Tyk2-IN-9	JAK	Inflammation/Immunology
Tyk2-IN-9 (Compound 26) is a selective Tyk-2 inhibitor with IC₅₀s of 0.076 and 1.8 nM for TYK2-JH2 and JAK1-JH2, respectively. Tyk2-IN-9 can be used for the research of inflammatory or autoimmune disease.

HY-143718

JAK3/BTK-IN-3	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-3 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-3 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 009)

HY-143717

JAK3/BTK-IN-2	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-2 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-2 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 004)

HY-143720

JAK3/BTK-IN-5	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-5 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-5 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147953A1, compound 35)

HY-143719

JAK3/BTK-IN-4	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-4 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-4 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147953A1, compound 003)

HY-143716

JAK3/BTK-IN-1	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-1 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-1 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 002).

HY-148141

JPE-1375	Complement System	Inflammation/Immunology
JPE-1375 is a complement C5a receptor 1 (C5aR1) antagonist. JPE-1375 effectively inhibits polymorphonuclear leukocyte mobilization (EC₅₀=6.9 µM) and reduces TNF levels (EC₅₀=4.5 µM) in mice. JPE-1375 can be used in studies of autoimmune and inflammatory diseases.

HY-144087

TYK2-IN-11	JAK	Inflammation/Immunology
TYK2-IN-11 (Compound 5B) is a selective Tyk-2 inhibitor with IC₅₀s of 0.016 and 0.31 nM for TYK2-JH2 and JAK1-JH2, respectively. TYK2-IN-11 can be used for the research of inflammatory or autoimmune disease.

HY-137298

LTA4H-IN-1	Aminopeptidase	Inflammation/Immunology
LTA4H-IN-1 is a potent inhibitor of leukotriene A4 hydrolase (LTA4H) extracted from patent WO2015092740A1, example 29, has an IC₅₀ of 2 nM. LTA4H-IN-1 can be used for the research of inflammatory and autoimmune disorders.

HY-151435

CCR6 antagonist 1	CCR	Inflammation/Immunology
CCR6 antagonist 1 is a CCR6 antagonist that inhibits the CCL20/CCR6 axis. CCR6 antagonist 1 can be used in the research of autoimmune-mediated inflammatory diseases, such as inflammatory bowel diseases (IBDs).

HY-144373

IL-17 modulator 6	Interleukin Related	Inflammation/Immunology
IL-17 modulator 6 (compound 61) is a potent Interleukin 17 (IL-17) modulator (pIC₅₀*=9.1). IL-17 modulator 6 has the ability to inhibit IL-17 and can be used for the research of inflammatory and autoimmune* diseases.**

HY-142703

RORγt inverse agonist 28	ROR	Inflammation/Immunology
RORγt inverse agonist 28 is a potent reverse agonist of RORγt. RORγt inverse agonist 28 regulates the differentiation of Th17 cells and inhibits the production of IL-17. RORγt inverse agonist 28 has the potential for the research of inflammation and autoimmune diseases (extracted from patent WO2021228215A1, compound 6) .

HY-145997

MRGPRX4 modulator-1	Others	Inflammation/Immunology
MRGPRX4 modulator-1 (compound 31-2) is a potent mas-related g-protein receptor X4 (MRGPR X4) modulator, with antagonist activity of IC₅₀ < 100 nM for MRGPR4. MRGPRX4 modulator-1 can be used for researching MRGPR X4 dependent diseases such as itch, pain, and autoimmune disorders.

HY-142806

RORγt inverse agonist 26	ROR	Inflammation/Immunology
RORγt inverse agonist 26 is a potent reverse agonist of RORγt. RORγt inverse agonist 26 regulates the differentiation of Th17 cells and inhibits the production of IL-17. RORγt inverse agonist 26 has the potential for the research of inflammation and autoimmune diseases (extracted from patent WO2021228215A1, compound 1) .

HY-143271

RORγt inverse agonist 29	ROR	Inflammation/Immunology
RORγt inverse agonist 29 is a potent, orally active and selective RORγt inverse agonist (IC₅₀: 21 nM). RORγt inverse agonist 29 can be used in the research of skin inflammation and autoimmune diseases like psoriasis.

HY-153103

LRRK2/NUAK1/TYK2-IN-1	LRRK2 JAK AMPK	Inflammation/Immunology
LRRK2/NUAK1/TYK2-IN-1 (conpound 226) shows inhibitory activity toward LRRK2 (Wt), LRRK2 (G2019), TYK2 and NUAK1, with IC₅₀ values lower than 10 nM. LRRK2/NUAK1/TYK2-IN-1 can be used for autoimmune disease research.

HY-148103

SR12418	REV-ERB	Inflammation/Immunology
SR12418 is a REV-ERB-specific synthetic ligand with IC₅₀s of 68 nM and 119 nM for REV-ERBα and REV-ERBβ, respectively. SR12418 can be used in experimental autoimmune encephalomyelitis (EAE) and colitis research.

HY-101265

Icanbelimod S1p receptor agonist 1	LPL Receptor	Inflammation/Immunology
Icanbelimod (S1p receptor agonist 1) is a potent and orally active?S1P?receptor agonist, exhibits an activity of inducing S1P1 internalization (EC₅₀=9.83 nM). Icanbelimod has the potential for the study of arthritis and EAE (experimental autoimmune encephalitis). Icanbelimod is extracted from patent WO2015039587A1, Compound 2.

HY-144031S

Tyk2-IN-8	JAK	Inflammation/Immunology
Tyk2-IN-8 is a selective Tyk-2 inhibitor with an IC50 of 5.7 nM for TYK2-JH2. Tyk2-IN-8 inhibits JAK1-JH1 with IC50 of 3.0 nM. Tyk2-IN-8 can be used for the research of autoimmune disease[1].

HY-15999A

Cerdulatinib hydrochloride PRT062070 hydrochloride; PRT2070 hydrochloride	Syk JAK	Cancer
Cerdulatinib hydrochloride (PRT062070) is a selective, oral active and reversible ATP-competitive inhibitor of dual SYK and JAK, with IC₅₀s of 32 nM, 0.5 nM, 12 nM, 6 nM and 8 nM for SYK and Tyk2, JAK1, 2, 3, respectively. Cerdulatinib hydrochloride could be used to research autoimmune disease and B-cell malignancies.

HY-151211

BTK-IN-16	Btk	Cancer Inflammation/Immunology
BTK-IN-16 is a dual inhibitor of BTK wild type and C481S mutant of Bruton’s tyrosine kinase (BTK) with IC₅₀s of 5.1 and 4.1 μM. BTK-IN-16 can be used for the research of autoimmune diseases and chronic lymphocytic leukemia.

HY-139907

DG013A	Others	Cancer Inflammation/Immunology
DG013A is a phosphinic acid tripeptide mimetic inhibitor. DG013A displays significantly weak affinity for both ERAP1 (IC₅₀=33 nM) and ERAP2 (IC₅₀=11 nM). DG013A can be used for the research of autoimmune disease and cancer.

HY-131342

BIIB068	Btk	Inflammation/Immunology
BIIB068 is a potent, selective, reversible and orally active BTK inhibitor with an IC₅₀ of 1 nM and a K_d of 0.3 nM. BIIB068 shows more >400-fold selective for BTK than other kinases. BIIB068 has the potential for autoimmune diseases research.

HY-101254

Luzindole N-0774	Melatonin Receptor	Neurological Disease
Luzindole (N-0774) is a selective melatonin receptor antagonist. Luzindole preferentially targets MT2 (Mel_1b) over MT1 (Mel_1a) with K_i values of 10.2 and 158 nM for human MT2 and MT1, respectively. Luzindole suppresses experimental autoimmune encephalomyelitis (EAE), and exerts antidepressant-like activity.

HY-143485

IRAK4-IN-9	IRAK	Cancer Inflammation/Immunology
IRAK4-IN-9 (compound 73) is a potent IRAK4 inhibitor with an IC₅₀ of 1.5 nM. IRAK4-IN-9 blocks MyD88 dependent signaling. IRAK4-IN-9 has the potential for the research of inflammatory diseases, autoimmune diseases, and cancer.

HY-143486

IRAK4-IN-10	IRAK	Cancer Inflammation/Immunology
IRAK4-IN-10 (compound 75) is a potent IRAK4 inhibitor with an IC₅₀ of 1.5 nM. IRAK4-IN-10 blocks MyD88 dependent signaling. IRAK4-IN-9 has the potential for the research of inflammatory diseases, autoimmune diseases, and cancer.

HY-152227

PROTAC TYK2 degradation agent1	PROTACs JAK	Inflammation/Immunology
PROTAC TYK2 degradation agent1 is a potent and subtype-selective TYK2 degrader. PROTAC TYK2 degradation agent1 has TYK2 degradation activity with DC₅₀ value of 14 nM. PROTAC TYK2 degradation agent1 can be used for the research of autoimmune disease.

HY-P9970

Infliximab Avakine; CT-P13	TNF Receptor Bacterial	Metabolic Disease Inflammation/Immunology Neurological Disease Cancer
Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research.

HY-145373

BMS-986143	Btk	Inflammation/Immunology
BMS-986143 is an orally active, reversible BTK inhibitor with an IC₅₀ of 0.26 nM. BMS-986143 also inhibits TEC, BLK, BMX, TXK FGR, YES1, ITK with IC₅₀s of 3 nM, 5 nM, 7 nM, 10 nM, 15 nM,19 nM, 21 nM, respectively. BMS-986143 can be used for the research of autoimmune diseases.

HY-139605

GLUT inhibitor-1	GLUT	Cancer Inflammation/Immunology
GLUT inhibitor-1 is a potent and orally active inhibitor of glucose transporters, targeting both GLUT1 and GLUT3, with IC₅₀s of 242 nM and 179 nM, respectively. GLUT inhibitor-1 has the potential for the reaesrch of cancers and autoimmune diseases.

HY-N8441

Neriifolin 17β-Neriifolin	Na+/K+ ATPase Apoptosis	Cancer Inflammation/Immunology
Neriifolin, a CNS-penetrating cardiac glycoside, is an inhibitor of the Na⁺, K⁺-ATPase. Neriifolin can target beclin 1, inhibits the formation of LC3-associated phagosomes and ameliorates experimental autoimmune encephalomyelitis (EAE) development. Neriifolin induces cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells^[2.

HY-146727

JAK3-IN-11	JAK	Inflammation/Immunology
JAK3-IN-11 (Compound 12), a potent, noncytotoxic, irreversible, orally active JAK3 inhibitor with IC₅₀ value of 1.7 nM, has excellent selectivity (>588-fold compared to other JAK isoforms), covalently bind to the ATP-binding pocket in JAK3. JAK3-IN-11 strongly inhibits JAK3-dependent signaling and T cell proliferation, is a promising tool for study *autoimmune* diseases.

HY-143864

S1PR1 agonist 1	LPL Receptor	Inflammation/Immunology
S1PR1 agonist 1 is a potent agonist of S1PR1. Sphingosine-1-phosphate (S1P) is a cell membrane-derived lysophospholipid signalling molecule that exerts its physiological functions mainly by stimulating some members of the G protein-coupled receptor family. S1PR1 agonist 1 has the potential for the research of autoimmune diseases (extracted from patent WO2021175223A1, compound 22).

HY-143865

S1PR1 agonist 2	LPL Receptor	Inflammation/Immunology
S1PR1 agonist 2 is a potent agonist of S1PR1. Sphingosine-1-phosphate (S1P) is a cell membrane-derived lysophospholipid signalling molecule that exerts its physiological functions mainly by stimulating some members of the G protein-coupled receptor family. S1PR1 agonist 2 has the potential for the research of autoimmune diseases (extracted from patent WO2021175225A1, compound 1).

HY-15771

Tirabrutinib ONO-4059; GS-4059	Btk Apoptosis	Cancer Inflammation/Immunology
Tirabrutinib (ONO-4059) is an orally active Bruton’s Tyrosine Kinase (BTK) inhibitor (can cross the blood-brain barrier (BBB)), with an IC₅₀ of 6.8 nM. Tirabrutinib irreversibly and covalently binds to BTK and inhibits aberrant B cell receptor signaling. Tirabrutinib can be used in studies of autoimmune diseases and hematological malignancies.

HY-15771A

Tirabrutinib hydrochloride ONO-4059 hydrochloride; GS-4059 hydrochloride	Btk Apoptosis	Cancer Inflammation/Immunology
Tirabrutinib (ONO-4059) hydrochloride is an orally active Bruton’s Tyrosine Kinase (BTK) inhibitor (can cross the blood-brain barrier (BBB)), with an IC₅₀ of 6.8 nM. Tirabrutinib hydrochloride irreversibly and covalently binds to BTK and inhibits aberrant B cell receptor signaling. Tirabrutinib hydrochloride can be used in studies of autoimmune diseases and hematological malignancies.

HY-144881

(S)-HH2853	Histone Methyltransferase	Cancer Inflammation/Immunology
(S)-HH2853 (compound 200), a PYRIDINO five membered aromatic ring compound, is a potent EZH1/2 dual inhibitor with an IC₅₀ of <100 nM for EZH2_Y641F. (S)-HH2853 has the potential to be used in the research of anti-tumor or autoimmune diseases.

HY-148272

IL-17A modulator-3	Interleukin Related	Cancer Inflammation/Immunology
IL-17A modulator-3 (compound 253) is a IL-17A modulator. IL-17A modulator-3 inhibits IL-17A/A with an IC₅₀ value ＜10 μM. IL-17A modulator-3 can be used for the research of inflammation, cancer and autoimmune disease.

HY-15770

TR-14035	Integrin	Inflammation/Immunology
TR-14035 is a orally active dual α₄β₇/α₄β₁ integrin antagonist, with IC₅₀ s of 7 nM and 87 nM for α₄β₇ and α₄β₁, respectively. TR-14035 can be used for the research of inflammation and autoimmune diseases.

HY-148335

IRG1-IN-1	Others	Cancer Infection Inflammation/Immunology
IRG1-IN-1 is an itaconic acid derivative. IRG1-IN-1 can inhibit immune-responsive gene 1 (IRG1) activity. IRG1-IN-1 can be used for the research of cancer, inflammation and autoimmune diseases.

HY-147584

BTK-IN-14	Btk	Cancer Inflammation/Immunology
BTK-IN-14 is a potent inhibitor of BTK. BTK plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-14 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022057894A1, compound 1).

HY-110216

5J-4	CRAC Channel	Inflammation/Immunology
5J-4 is a potent CRAC inhibitor. 5J-4 decreases the numbers of infiltrated mononuclear cell into the CNS, and significantly decreases the population of infiltrated CD4+ population. 5J-4 reduces the symptoms and delayed the onset of EAE (experimental autoimmune encephalomyelitis) in mouse model of inflammation.

HY-147581

BTK-IN-11	Btk	Cancer Inflammation/Immunology
BTK-IN-11 is a potent inhibitor of BTK. BTK plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-11 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022063101A1, compound Z2).

HY-108810

Canakinumab Ilaris; ACZ 885	Interleukin Related	Inflammation/Immunology
Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC₅₀ values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin.

HY-13591

Piclidenoson IB-MECA; CF-101	Adenosine Receptor Apoptosis	Cancer Inflammation/Immunology
Piclidenoson (IB-MECA) is a first-in-class, orally active and selective A3 adenosine receptor (A3AR) agonist. Piclidenoson exhibits antiproliferative effect and induces apoptosis in different cancer cell types like melanoma, leukemia. Piclidenoson can be used for the research of autoimmune inflammatory diseases and COVID-19.

HY-138990

GK563	Phospholipase Apoptosis	Inflammation/Immunology
GK563 is a selective Ca²⁺-independent phospholipase A₂ (GVIA iPLA₂) inhibitor with an IC₅₀ value of 1 nM. GK563 is 22000 times more active against GVIA iPLA₂ than GIVA cPLA₂. GK563 reduces β-cell apoptosis induced by proinflammatory cytokines, raising the possibility that it can be beneficial in countering autoimmune diseases, such as type 1 diabetes.

HY-17606

Cenerimod ACT-334441	LPL Receptor	Inflammation/Immunology
Cenerimod (ACT-334441) is a potent, selective and orally active S1P1 receptor modulator, with an EC₅₀ of 1 nM. Cenerimod shows more than 36‐fold selctivity for hS1P1 over hS1P2, hS1P3, hS1P4, and hS1P5 receptor subtypes (EC₅₀s=>10000, 228, 2134, and 36 nM, respectively). Cenerimod can attenuate murine experimental autoimmune encephalomyelitis (EAE) and murine sclerodermatous.

HY-114419

Zetomipzomib KZR-616	Proteasome	Inflammation/Immunology
Zetomipzomib (KZR-616), a first-in-class inhibitor of the immunoproteasome, selectively targets the LMP7 (IC₅₀: 39/57 nM=hLMP7/mLMP7) and LMP2 (IC₅₀: 131/179 nM=hLMP7/mLMP7) subunits of the immunoproteasome. Zetomipzomib has the potential for the research of multiple autoimmune diseases.

HY-114419A

Zetomipzomib maleate KZR-616 maleate	Proteasome	Inflammation/Immunology
Zetomipzomib (KZR-616) maleate, a first-in-class immunoproteasome inhibitor, selectively targets the LMP7 (IC₅₀: 39/57 nM=hLMP7/mLMP7) and LMP2 (IC₅₀: 131/179 nM=hLMP2/mLMP2) subunits of the immunoproteasome. Zetomipzomib maleate has the potential for the research of multiple autoimmune diseases.

HY-P99220

Tabalumab LY2127399	TNF Receptor	Inflammation/Immunology
Tabalumab (LY2127399) is a humanised anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus.

HY-147051

MRGPRX4 modulator-2	Others	Inflammation/Immunology
MRGPRX4 modulator-2 (compound 1-55) is a potent MRGPR X4 modulator, possessing antagonist activity against MRGPR X4 with an IC₅₀ < 100 nM. MRGPRX4 modulator-2 can be used for researching autoimmune diseases such as psoriasis, multiple sclerosis, Steven Johnson’s Syndrome, and other chronic itch conditions.

HY-129624A

Bisindolylmaleimide VIII acetate Ro 31-7549 acetate; Bis VIII acetate	PKC Apoptosis	Cancer Inflammation/Immunology
Bisindolylmaleimide VIII acetate (Ro 31-7549 acetate) is a potent and selective protein kinase C (PKC) inhibitor with an IC₅₀ of 158 nM for rat brain PKC. Bisindolylmaleimide VIII acetate has IC₅₀s of 53, 195, 163, 213, and 175 nM for PKC-α, PKC-β_I, PKC-β_II, PKC-γ, PKC-ε, respectively. Bisindolylmaleimide VIII acetate facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases.

HY-147579

Axl-IN-12	TAM Receptor	Cancer Infection Inflammation/Immunology
Axl-IN-12 (Example 2) is a potent AXL inhibitor. Axl-IN-12 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancers, viral infectious diseases or other diseases of mammals.

HY-148475

NF-κB-IN-7	NF-κB	Cancer Infection Metabolic Disease Inflammation/Immunology Cardiovascular Disease
NF-κB-IN-7 (compound 1B) is a potent NF-κB inhibitor. NF-κB-IN-7 can be used for the research of cancer, inflammation, autoimmune diseases, diabetes and diabetes complications, infections, cardiovascular disease and defective reperfusion injury.

HY-133807

Benpyrine	TNF Receptor	Inflammation/Immunology
Benpyrine is a highly specific and orally active TNF-α inhibitor with a K_D value of 82.1 μM. Benpyrine tightly binds to TNF-α and blocks its interaction with TNFR1, with an IC₅₀ value of 0.109 µM. Benpyrine has the potential for TNF-α mediated inflammatory and autoimmune disease research.

HY-101019

Ossirene AS101	Interleukin Related Caspase	Cancer Inflammation/Immunology
Ossirene (AS101), an immunomodulatory tellurium compound, is a potent IL-1β inhibitor. Ossirene abolishes phosphorylation of STAT3 by inhibiting IL-10. Ossirene potently inhibits Caspase-1 and is used for the autoimmune diseases and certain malignancies.

HY-147578

Axl-IN-11	TAM Receptor	Cancer Infection Inflammation/Immunology
Axl-IN-11 (Example 1) is a potent AXL inhibitor. Axl-IN-11 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancers, viral infectious diseases or other diseases of mammals.

HY-149051

BGB-8035	Btk	Cancer Inflammation/Immunology
BGB-8035 is an orally active, highly selective bruton's tyrosine kinase (BTK) inhibitor with IC₅₀s of 1.1 nM, 99 nM, 621 nM for BTK, TEC, EGFR, respectively. BGB-8035 has antitumor and anti-arthritis activity. BGB-8035 has the potential for B-cell malignancies and autoimmune diseases research.

HY-108039

HE 3286 NE-3107	NF-κB	Metabolic Disease Inflammation/Immunology Neurological Disease
HE 3286 is a synthetic derivative of a natural anti-inflammatory steroid, β-AET. HE 3286 is an orally active partial NF-κB inhibitor. HE3286 reduces proinflammatory signals, including IL-6 and matrix metallopeptidase 3. HE 3286 freely penetrates the blood brain barrier in mice. HE 3286 can be used for the research of the ulcerative colitis, arthritis, experimental autoimmune encephalomyelitis.

HY-15509A

Semapimod tetrahydrochloride CNI-1493; CPSI-2364 tetrahydrochloride	TNF Receptor Interleukin Related p38 MAPK	Inflammation/Immunology
Semapimod tetrahydrochloride (CNI-1493), an inhibitor of proinflammatory cytokine production, can inhibit TNF-α, IL-1β, and IL-6. Semapimod tetrahydrochloride inhibits TLR4 signaling (IC₅₀≈0.3 μM). Semapimod tetrahydrochloride inhibits p38 MAPK and nitric oxide production in macrophages. Semapimod tetrahydrochloride has potential in a variety of inflammatory and autoimmune disorders.

HY-117213

Ex26 S1P1-IN-Ex26	LPL Receptor	Metabolic Disease Inflammation/Immunology Neurological Disease
Ex26 (S1P1-IN-Ex26) is a potent and selective sphingosine 1-phosphate receptor 1 (S1P₁) antagonist (IC₅₀=0.93 nM). Ex26 shows >3,000-fold selectivity for S1P₁ over other Sphingosine 1-phosphate receptors. Ex26 can be used in experimental autoimmune encephalomyelitis reseach.

HY-114170

ML604440	Proteasome	Inflammation/Immunology
ML604440 is a specific and cell-permeable Proteasome β1i (LMP2) subunit inhibitor. ML604440 can be used in experimental colitis, EAE and autoimmune disease research. ML604440 shows synergistic effects and advantageous when combined with LMP7 inhibitor.

HY-145885

TLR7/8 agonist 6	Toll-like Receptor (TLR)	Cancer Infection Inflammation/Immunology
TLR7/8 agonist 6 (Compound 4) is the potent agonist of TLR7/8 with IC₅₀s of 0.18 and 5.34 μM, respectively. TLR7/8 agonist 6 is an imidazoquinoline derivative compound. Toll-like receptors (TLRs) 7 and 8 are key targets in the development of immunomodulatory drugs for researching infectious disease, cancer, and autoimmune disorders.

HY-145430

IL-17A modulator-1	Interleukin Related	Cancer Inflammation/Immunology Neurological Disease
IL-17A modulator-1 is a IL-17A modulator, extracted from patent WO2021239743+A1, example 9. IL-17A modulator-1 inhibits the biological action of IL-17A with a pIC₅₀ of 8.2. IL-17A modulator-1 can be used for the research of diseases or disorders associated with modulation of IL-17A activity including diseases with an immune component or autoimmune pathol, cancer and neurodegenerative disorders.

HY-147576

Axl-IN-9	TAM Receptor	Cancer Inflammation/Immunology
Axl-IN-9 (Example 10) is a potent AXL inhibitor, with an IC₅₀ of 26 nM. Axl-IN-9 has excellent transmembrane properties. Axl-IN-9 exhibits excellent pharmacokinetic properties in an animal body. Axl-IN-9 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancer, or other diseases in mammals.

HY-120785

SR1555	ROR	Inflammation/Immunology
SR1555 is a specific retinoic acid receptor-related orphan nuclear receptor γ (RORγ) inverse agonist with an IC₅₀ value of 1 μM. SR1555 not only inhibits TH17 cell development and function but also increases the frequency of T regulatory cells, as well as inhibits the expression of IL-17. SR1555 can be used for researching autoimmune diseases.

HY-147577

Axl-IN-10	TAM Receptor	Cancer Inflammation/Immunology
Axl-IN-10 (Example 1) is a potent AXL inhibitor, with an IC₅₀ of 5 nM. Axl-IN-10 has excellent transmembrane properties.Axl-IN-10 exhibits excellent pharmacokinetic properties in an animal body. Axl-IN-10 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancer, or other diseases in mammals.

HY-11062

Icilin AG-3-5	TRP Channel	Inflammation/Immunology Neurological Disease
Icilin (AG-3-5) is a super-agonist of the transient receptor potential M8 (TRPM8) ion channel. Icilin activates TRPM8 in EGTA in a dose-dependent manner (EC₅₀=1.4 μM). Icilin is a “super-cooling agent”. Icilin attenuates autoimmune neuroinflammation through modulation of the T-cell response.

HY-145886

TLR7/8 antagonist 1	Toll-like Receptor (TLR)	Cancer Infection Inflammation/Immunology
TLR7/8 Antagonist 1 (Compound 16c) is the potent antagonist of TLR7/8 with IC₅₀s of 3.91 and 2.19 μM, respectively. TLR7/8 Antagonist 1 is an imidazoquinoline derivative compound. Toll-like receptors (TLRs) 7 and 8 are key targets in the development of immunomodulatory drugs for researching infectious disease, cancer, and autoimmune disorders.

HY-105037

Forigerimod IPP-201101	Autophagy	Inflammation/Immunology
Forigerimod (IPP-201101) is a CD4 T-cell modulator. Forigerimod is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .

HY-P4040

Ac-D-DGla-LI-Cha-C	HCV Protease	Cancer Infection Metabolic Disease Inflammation/Immunology Neurological Disease
Ac-D-DGla-LI-Cha-C is a potent HCV protease inhibitor peptide. Ac-D-DGla-LI-Cha-C can be used for the research of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases.

HY-P99190

Eldelumab BMS-936557; MDX-1100	CXCR	Inflammation/Immunology
Eldelumab (BMS-936557) is a humanised anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease.

HY-105037A

Forigerimod TFA IPP-201101 TFA	Autophagy	Inflammation/Immunology
Forigerimod TFA (IPP-201101 TFA) is a CD4 T-cell modulator. Forigerimod TFA is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod TFA can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .

HY-103637

Vimirogant VTP-43742	ROR	Inflammation/Immunology
Vimirogant (VTP-43742) is a potent, selective, and orally active RORγt inhibitor (K_i=3.5 nM; IC₅₀=17 nM). Vimirogant exhibits >1000-fold selectivity versus the RORα and RORβ isotypes. Vimirogant inhibits Th17 differentiation and IL-17A secretion from mouse splenocytes (IC₅₀=57 nM) without affecting Th1, Th2, or Treg cell differentiation. Vimirogant has the potential for autoimmune disorders research.

HY-N10768

1-Dehydro-[10]-gingerdione	IKK NF-κB	Inflammation/Immunology
1-Dehydro-[10]-gingerdione directly inhibits IKKβ activity by targeting the activation loop of IKKβ, thus disrupting IKKβ-catalysed IκBα phosphorylation in macrophages stimulated with agonists. 1-Dehydro-[10]-gingerdione inhibits LPS (HY-D1056)-induced NF-κB transcriptional activity. 1-Dehydro-[10]-gingerdione has the potential for NF-κB-associated inflammation and autoimmune disorders research.

HY-103637A

Vimirogant hydrochloride VTP-43742 hydrochloride	ROR	Inflammation/Immunology
Vimirogant (VTP-43742) hydrochloride is a potent, selective, and orally active RORγt inhibitor (K_i=3.5 nM; IC₅₀=17 nM). Vimirogant hydrochloride exhibits >1000-fold selectivity versus the RORα and RORβ isotypes. Vimirogant hydrochloride inhibits Th17 differentiation and IL-17A secretion from mouse splenocytes (IC₅₀=57 nM) without affecting Th1, Th2, or Treg cell differentiation. Vimirogant hydrochloride has the potential for autoimmune disorders research.

HY-111360

SPL-707	γ-secretase	Inflammation/Immunology
SPL-707 is an orally active, selective signal peptide peptidase-like 2a (SPPL2a) inhibitor with an IC₅₀ of 77 nM for hSPPL2a. SPL-707 inhibits γ-secretase (IC₅₀=6.1 μM) and SPP (IC₅₀=3.7 μM). SPL-707 has the potential for autoimmune diseases research by targeting B cells and dendritic cells.

HY-151096

ACT-660602	CXCR	Inflammation/Immunology
ACT-660602 is an orally active antagonist of chemokine receptor (CXCR3) with an IC₅₀ value of 204 nM. ACT-660602 inhibits T-cell migration and shows efficacy in acute lung ingury model. ACT-660602 can be used for autoimmune diseases research.

HY-44062

G9a-IN-1	Histone Methyltransferase	Inflammation/Immunology Cancer
G9a-IN-1 (Compound 113) is a G9a protein inhibitor. G9A/EHMT2 is a nuclear histone lysine methyltransferase that catalyzes histone H3 lysine 9 dimethylation (H3K9me2), which is a reversible modification generally associated with transcriptional gene silencing. G9a-IN-1 can be used for the research of autoimmune disorders or cancer.

HY-115777

ARN-6039
ROR Neurological Disease

ARN-6039 is an orally available inverse agonist of RORγ for autoimmune demyelinating disease.

HY-P9913

Rituximab Anti-Human CD20 type I, Chimeric Antibody	CD20	Cancer Inflammation/Immunology
Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.

HY-B1087

Prednisolone hemisuccinate Prednisolone 21-hemisuccinate	Glucocorticoid Receptor	Inflammation/Immunology
Prednisolone hemisuccinate is a synthetic glucocorticoid, a derivative of cortisol, which is used to treat a variety of inflammatory and auto-immune conditions.

HY-139567

Afimetoran BMS-986256	Toll-like Receptor (TLR)	Inflammation/Immunology
Afimetoran is a toll-like receptor antagonist, which can be used in the research of inflammatory and autoimmune diseases.

HY-128703

Bromodomain inhibitor-8	Epigenetic Reader Domain	Inflammation/Immunology
Bromodomain inhibitor-8 (Intermediate 21) is a BET bromodomain inhibitor for treating autoimmune and inflammatory diseases.

HY-143721

SSAO inhibitor-2	Monoamine Oxidase	Metabolic Disease Cardiovascular Disease Inflammation/Immunology
SSAO inhibitor-2 (Compound 1) is a semicarbazide-sensitive amine oxidase (SSAO) inhibitor with IC₅₀s of <10 nM, and 10-100 μM for human SSAO and MAO-A, respectively. SSAO inhibitor-3 can be used for the research of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune diseases, multiple sclerosis, etc.

HY-143723

SSAO inhibitor-3	Monoamine Oxidase	Metabolic Disease Cardiovascular Disease Inflammation/Immunology
SSAO inhibitor-3 (Compound 2) is a semicarbazide-sensitive amine oxidase (SSAO) inhibitor with IC₅₀s of <10 nM, and 0.1-10 μM for human SSAO and AOC1, respectively. SSAO inhibitor-3 can be used for the research of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune diseases, multiple sclerosis, etc.

HY-109175

Fosifidancitinib	JAK	Inflammation/Immunology
Fosifidancitinib is a potent and selective inhibitor of JAK kinases 1/3. Fociatinib is used in studies of allergies, asthma and autoimmune diseases.

HY-132807

Amdizalisib
HMPL-689
PI3K Cancer Inflammation/Immunology

Amdizalisib (HMPL-689) is a PI3K inhibitor and used for the research of inflammatory disease, autoimmune disease or cancer.

HY-125099A

AFM-30a hydrochloride	Protein Arginine Deiminase	Cancer Inflammation/Immunology
AFM-30a hydrochloride is a potent protein arginine deiminase 2 (PAD2) inhibitor and has excellent PAD2-selectivity. AFM-30a hydrochloride binds to PAD2 with an EC₅₀ value of 9.5 μM. AFM-30a hydrochloride also inhibits H3 citrullination with an EC₅₀ value of 0.4 μM. AFM-30a hydrochloride can be used for the research of certain cancers and a variety of autoimmune diseases including rheumatoid arthritis (RA), multiple sclerosis, lupus, and ulcerative colitis.

HY-125099

AFM-30a	Protein Arginine Deiminase	Cancer Inflammation/Immunology
AFM-30a is a potent protein arginine deiminase 2 (PAD2) inhibitor and has excellent PAD2-selectivity. AFM-30a binds to PAD2 with an EC₅₀ value of 9.5 μM. AFM-30a also inhibits H3 citrullination with an EC₅₀ value of 0.4 μM. AFM-30a can be used for the research of certain cancers and a variety of autoimmune diseases including rheumatoid arthritis (RA), multiple sclerosis, lupus, and ulcerative colitis.

HY-139555

Zectivimod	LPL Receptor	Inflammation/Immunology
Zectivimod is a sphingosine-1-phosphate receptor agonist. Zectivimod can be used for the research of autoimmune diseases, chronic inflammatory diseases and immunoregulation disorders.

HY-N2335

Coumestrol	Estrogen Receptor/ERR	Cancer
Coumestrol, a phytoestrogen present in soybean products, exhibits activities against cancers, neurological disorders, and autoimmune diseases. It suppresses proliferation of ES2 cells with an IC₅₀ of 50 μM.

HY-N10520

Pectic acid Methyl protopectin; Polygalacturonic acid	Apoptosis Necroptosis Endogenous Metabolite	Cancer Inflammation/Immunology
Pectic acid (Methyl protopectin), a polygalacturonic acid, induces cell apoptosis and necrosis in pituitary tumor cells. Pectic acid can be used in the research of cancers and autoimmune disease.

HY-P9913A

Rituximab (anti-CD20)	CD20	Cancer Inflammation/Immunology
Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer.

HY-109178

Ifidancitinib ATI-50002; ATI-502	JAK	Others
Ifidancitinib (ATI-50002) is a potent and selective inhibitor of JAK kinases 1/3. Ifidancitinib can be used in studies of allergies, asthma and autoimmune diseases.

HY-N7703

D-Mannuronic acid sodium	Others	Inflammation/Immunology
D-Mannuronic acid sodium, isolated from Macrocystis pyrifera, has the potential in autoimmune encephalomyelitis (EAE), adjuvant induced arthritis (AIA), nephrotic syndrome, and acute glomerulonephritis studies.

HY-N2279

Kurarinone	Others	Inflammation/Immunology
Kurarinone, a flavanoid derived from shrub Sophora flavescens, inhibits the process of experimental autoimmune encephalomyelitis via blocking Th1 and Th17 cell differentiation.

HY-N11451

Lacto-N-fucopentaose III LNFP-III	Arginase Aldehyde Dehydrogenase (ALDH) Indoleamine 2,3-Dioxygenase (IDO)	Inflammation/Immunology
Lacto-N-fucopentaose III (LNFP-III) is an immune modulator. Lacto-N-fucopentaose III reduces the severity of experimental autoimmune encephalomyelitis (EAE) and CNS inflammation.

HY-108564

L 655240	Prostaglandin Receptor	Cardiovascular Disease
L 655240 is thromboxane antagonist. L 655240 attenuates early ischemia- and reperfusion-induced arrhythmias in a canine model of coronary artery occlusion. L 655240 also involves in cancer and autoimmune disorders.

HY-147533

RORγt inverse agonist 30	ROR	Inflammation/Immunology
RORγt inverse agonist 30 (Compound 1) is a potent RORγt inverse agonist with the IC₅₀ of 46 nM. Targeting the nuclear receptor RORγt is effective in autoimmune disorders.

HY-145434

IL-17 modulator 5
Interleukin Related Inflammation/Immunology

IL-17 modulator 5 (compound 26) is a IL-17 inhibitor, with an IC₅₀ of 1 nM.

HY-13943

CNX-774	Btk	Cancer
CNX-774 is an orally active, irreversible and selective BTK inhibitor, with an IC₅₀ of < 1 nM. CNX-774 specifically targets Cysteine 481 of Btk for covalent modification.

HY-32340

Lexacalcitol KH1060	VD/VDR	Cancer Inflammation/Immunology
Lexacalcitol (KH1060), a vitamin D analog, is a potent regulator of cell growth and immune responses. Lexacalcitol can be used for the research of graft rejection, psoriasis, cancer and auto-immune diseases.

HY-P99310

Perakizumab RG4934; Anti-Human IL17A Recombinant Antibody	Interleukin Related	Inflammation/Immunology
Perakizumab (RG4934) is a humanized IgG1κ monoclonal antibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis.

HY-P99670

Iscalimab CFZ-533; OM11-62MF	TNF Receptor	Metabolic Disease Inflammation/Immunology
Iscalimab (CFZ-533) is a non-depleting IGg1 monoclonal antibody targeting CD40 (K_D: 0.3 nM). Iscalimab can be used for research of Graves' hyperthyroidism and autoimmune diseases.

HY-148412

Monarsen EN101; ODN 7040; BL 7040	Cholinesterase (ChE)	Others
Monarsen (EN101) is a synthetic 20-base antisense oligodeoxynucleotide directed against the human AChE gene. Monarsen is used in the study of Autoimmune myasthenia gravis (MG), a neuromuscular disorder caused by autoantibodies directed against the acetylcholine receptor (AChR).

HY-111947

c-Fms-IN-6	c-Fms	Inflammation/Immunology
c-Fms-IN-6 is a potent inhibitor of c-FMS, with an IC₅₀ of ≤10 nM for unphosphorylated c-FMS, also weakly inhibits unphosphorylated c-KIT and PDGFR (IC₅₀, > 1 μM). Used in the research of autoimmune diseases.

HY-148317

PI3Kγ inhibitor 6	PI3K	Inflammation/Immunology
PI3Kγ inhibitor 6 (compound 9) is a PI3Kγ inhibitor. PI3Kγ inhibitor 6 can be used for the research of inflammatory and autoimmune diseases.

HY-131974

Glucocorticoid receptor agonist-1	Glucocorticoid Receptor	Inflammation/Immunology
Glucocorticoid receptor agonist-1 is a potent glucocorticoid receptor agonist with an IC₅₀ of 2.8 nM extracted from patent WO2017210471A1, compound 41.

HY-114495

Caerulomycin A Cerulomycin; Caerulomycin	Fungal Antibiotic	Infection Inflammation/Immunology
Caerulomycin A (Cerulomycin; Caerulomycin), an antifungal compound, induces generation of T cells, enhances TGF-β-Smad3 protein signaling via suppressing interferon-γ-induced STAT1 signaling. Antifungal and antibiotic activity, and used in autoimmune diseases.

HY-101786

KZR-504	Proteasome	Inflammation/Immunology
KZR-504 is a highly selective inhibitor of immunoproteasome low molecular mass polypeptide 2 (LMP2), with IC₅₀s of 51 nM, 4.274 μM for LMP2 and LMP7, respectively. KZR-504 is of interest for the treatment of autoimmune disease.

HY-P99728

Melredableukin alfa RG7835; RO7049665	Interleukin Related	Inflammation/Immunology
Melredableukin alfa (RO-7049665) is a fusion protein that consists of a human IgG1-κ fused to a mutated human interleukin 2 (IL2 mutein) via a peptide linker. Melredableukin alfa can be used for the research of autoimmune hepatitis and ulcerative colitis.

HY-P3507

Dalazatide ShK-186	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease.

HY-19702

PKR activator 3	Pyruvate Kinase	Cancer Metabolic Disease Inflammation/Immunology
PKR activator 3 is a pyruvate kinase isoform PKR activator extracted from patent WO2014139144A1, compound 160. PKR activator 3 can be used for the research of PKR function related diseases, including cancer, diabetes, obesity, autoimmune disorders, and benign prostatic hyperplasia.

HY-75385

Zaurategrast ethyl ester CDP323; UCB1184197	Integrin	Inflammation/Immunology
Zaurategrast ethyl ester (CDP323), the ethyl ester proagent of CT7758, is a α4β1/α4β7 integrin antagonist used for the treatment of inflammatory and autoimmune disorders.

HY-139323

TLR7/8-IN-1	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7/8-IN-1 is a crystalline from of a TLR7/TLR8 inhibitor extracted from patent WO2019220390, compound 2b. TLR7/8-IN-1 can be used for the research of autoimmune disease.

HY-P3507A

Dalazatide TFA ShK-186 TFA	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease.

HY-136179

ZAP-180013	Tyrosinase	Inflammation/Immunology
ZAP-180013 is a zeta-chain-associated protein kinase 70 (ZAP-70) inhibitor with an IC₅₀ of 1.8 μM. ZAP-180013 inhibits the interaction of ZAP-70 SH2 domain with immunoreceptor tyrosine-based activation motif (ITAMs).

HY-150095

YE6144	Others	Inflammation/Immunology
YE6144 is a prototypical interferon regulatory factor 5 (IRF5) inhibitor. YE6144 selectively suppresses IRF5 activity through inhibition of IRF5 phosphorylation.

HY-132196

BTK inhibitor 18	Btk	Inflammation/Immunology
BTK inhibitor 18 is a potent, selective,orally active and covalent Btk inhibitor with a IC₅₀ of 142 nM. BTK inhibitor 18 has anti-inflammatory activities.

HY-124759

CCR1 antagonist 9
CCR Inflammation/Immunology

CCR1 antagonist 9 is a potent and selective CCR1 antagonist with an IC₅₀ of 6.8 nM in calcium flux assay.
HY-101251

AMT hydrochloride
NO Synthase Inflammation/Immunology

AMT hydrochloride is a selective inhibitor of inducible NOS (iNOS) with K_i of 4.2 nM.
HY-116146

CYM50179
LPL Receptor Inflammation/Immunology

CYM50179 (compound 22n) is a potent and selective S1P4-R (Sphingosine-1-phosphate4 receptor) agonist with an EC₅₀ of 46 nM.

HY-134836

STM2457	Apoptosis	Cancer
STM2457 is a first-in-class, highly potent, selective and orally active METTL3 inhibitor with an IC₅₀ of 16.9 nM. STM2457 can be used for the research of acute myeloid leukaemia (AML).

HY-107568

Iodophenpropit dihydrobromide	Histamine Receptor	Inflammation/Immunology
Iodophenpropit dihydrobromide is a potent and selective histamine H3 receptor antagonist. The binding of [¹²⁵I]Iodophenpropit is selective, saturable, readily reversible, and of high affinity (K_D 0.32 nM).

HY-135304

PAD-IN-2	Protein Arginine Deiminase	Cancer Inflammation/Immunology
PAD-IN-2 is a potent pad4 inhibitor (IC₅₀: <1 μM). PAD-IN-2 can be used in the research of auto-immune diseases and cancers, such as rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cystic fibrosis, asthma, multiple sclerosis and psoriasis.

HY-14908

Vidofludimus 4sc-101; SC12267	Dihydroorotate Dehydrogenase Interleukin Related FXR	Infection Inflammation/Immunology
Vidofludimus is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus also can be used for the research of fatty liver by targeting FXR.

HY-75385A

Zaurategrast ethyl ester sulfate CDP323 sulfate; UCB1184197 sulfate	Integrin	Inflammation/Immunology
Zaurategrast ethyl ester sulfate (CDP323 sulfate), the ethyl ester proagent of CT7758, is a α4β1/α4β7 integrin antagonist used for the treatment of inflammatory and autoimmune disorders.

HY-P99793

Orticumab MLDL1278A	LDLR	Inflammation/Immunology
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement.

HY-130243

RORγt Inverse agonist 6	ROR	Inflammation/Immunology
RORγt Inverse agonist 6 (compound 43) is a RORγt inverse agonist for the study of Th17-driven autoimmune diseases. RORγt Inverse agonist 6 (compound 43) suppresses IL-17A gene expression by IL-23 stimulation in vivo.

HY-P99289

Epratuzumab Antibody hLL 2; Anti-Human CD22 Recombinant Antibody	CD22	Cancer Inflammation/Immunology
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases.

HY-P99335

Vunakizumab Anti-Human IL17A Recombinant Antibody	Interleukin Related	Inflammation/Immunology
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis.

HY-109854A

(R)-Lisofylline (R)-Lisophylline	STAT	Metabolic Disease Inflammation/Immunology
(R)-Lisofylline ((R)-Lisophylline) is a (R)-enantiomer of the metabolite of Pentoxifylline with anti-inflammatory properties. (R)-Lisofylline is a lysophosphatidic acid acyltransferase inhibitor with an IC₅₀ of 0.6 µM and interrupts IL-12 signaling-mediated STAT4 activation. (R)-Lisofylline has the potential for type 1 diabetes, autoimmune disorders research.

HY-108829

Abatacept CTLA4lg; BMS-188667	CTLA-4	Inflammation/Immunology Cancer
Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases.

HY-P99385

Vobarilizumab ALX-0061	Interleukin Related	Inflammation/Immunology
Vobarilizumab (ALX-0061) is an anti-IL-6R monoclonal antibody (mAb) (K_d: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis.

HY-117433

4-Hydroperoxy cyclophosphamide	DNA Alkylator/Crosslinker Apoptosis Reactive Oxygen Species Drug Metabolite	Inflammation/Immunology
4-Hydroperoxy cyclophosphamide is the active metabolite form of the proagent Cyclophosphamide. 4-Hydroperoxy cyclophosphamide crosslinks DNA and induces T cell apoptosis independent of death receptor activation, but activates mitochondrial death pathways through production of reactive oxygen species (ROS). 4-Hydroperoxy cyclophosphamide has the potential for lymphomas and autoimmune disorders.

HY-18620

DZ2002	Others	Inflammation/Immunology
DZ2002 is an orally active, reversible and low-cytotoxic type III SAHH inhibitor (K_i=17.9 nM), with good immunosuppressive activity. DZ2002 prevents the development of experimental dermal fibrosis by reversing the profibrotic phenotype of various cell types. DZ2002 can be used in studies of autoimmune diseases such as lupus syndrome and systemic sclerosis.

HY-120438

TASP0415914	PI3K Akt	Inflammation/Immunology
TASP0415914 is a potent and orally active PI3Kγ inhibitor with an IC₅₀ of 29 nM. TASP0415914 also shows potent Akt inhibitory activities with an IC₅₀ of 294 nM. TASP0415914 can be used for inflammatory diseases research.

HY-50856S

Deuruxolitinib CTP-543; Ruxolitinib d₈; Deuterated Ruxolitinib	JAK	Inflammation/Immunology
Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), modulates the activity of JAK1/JAK2. Deuruxolitinib can be used for the research hair loss disorders (from patent WO2017192905A1, compound I).

HY-135810

Cletoquine Desethylhydroxychloroquine	Influenza Virus Parasite	Infection Inflammation/Immunology
Cletoquine (Desethylhydroxychloroquine) is a major active metabolite of Hydroxychloroquine. Cletoquine is produced in the liver by CYP2D6, CYP3A4, CYP3A5, and CYP2C8 isoenzymes. Cletoquine is also a Chloroquine derivative and has the ability to against the chikungunya virus (CHIKV). Cletoquine has antimalarial effects and has the potential for autoimmune diseases treatment.

HY-153077

PFKFB3-IN-2	Phosphatase	Cancer Metabolic Disease Inflammation/Immunology Neurological Disease
PFKFB3-IN-2 is a 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) inhibitor. PFKFB3-IN-2 has potential applications in cancer, neurodegenerative diseases, autoimmune diseases, inflammatory diseases, multiple sclerosis, metabolic diseases, angiogenesis inhibition and other diseases.

HY-14908A

Vidofludimus hemicalcium 4sc-101 hemicalcium; SC12267 hemicalcium	Dihydroorotate Dehydrogenase Interleukin Related FXR	Infection Inflammation/Immunology
Vidofludimus (4sc-101; SC12267) hemicalcium is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus hemicalcium, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus hemicalcium also can be used for the research of fatty liver by targeting FXR.

HY-10405

Pamapimod Ro4402257; R1503	p38 MAPK Autophagy	Inflammation/Immunology
Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC₅₀s of 14 nM and 480 nM and K_is of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment.

HY-151363

IRAK4-IN-21	IRAK	Inflammation/Immunology
IRAK4-IN-21 (compound 17) is an orally active, potent and selective IRAK4 inhibitor with IC₅₀ values of 5 and 56 nM for IRAK4 and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC₅₀=0.17 µM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis.

HY-135810A

Cletoquine oxalate Desethylhydroxychloroquine oxalate	Influenza Virus Parasite	Infection Inflammation/Immunology
Cletoquine oxalate (Desethylhydroxychloroquine oxalate) is a major active metabolite of Hydroxychloroquine. Cletoquine oxalate is produced in the liver by CYP2D6, CYP3A4, CYP3A5, and CYP2C8 isoenzymes. Cletoquine oxalate is also a Chloroquine derivative and has the ability to against the chikungunya virus (CHIKV). Cletoquine oxalate has antimalarial effects and has the potential for autoimmune diseases treatment.

HY-107429

Abrocitinib PF-04965842	JAK	Inflammation/Immunology
Abrocitinib (PF-04965842) is a potent, orally active and selective JAK1 inhibitor, with IC₅₀s of 29 and 803 nM for JAK1 and JAK2, respectively. Abrocitinib (PF-04965842) exhibits less active effect on TYK2 (IC₅₀, 1.253 μM), and inhibits phosphorylation of STAT1, STAT3 and STAT5 after stimulation. Effective in autoimmune disease.

HY-151365

IRAK4-IN-22	IRAK	Inflammation/Immunology
IRAK4-IN-22 (compound 18) is an orally active, potent and selective IRAK4 inhibitor with IC₅₀ values of 3 and 17 nM for IRAK4 and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC₅₀=0.10 µM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis.

HY-136301

Acid secretion-IN-1	Others	Inflammation/Immunology
Acid secretion-IN-1 is a polycyclic compound extracted from patent WO2018024188A1, Compound Example 17.4. Acid secretion-IN-1 is synthesized and used in the IDO inhibitor synthetic experiment.

HY-136427

KRM-III	Nuclear Factor of activated T Cells (NFAT)	Inflammation/Immunology
KRM-III is a potent and orally active T-cell antigen receptor (TCR) inhibitor. KRM-III inhibits TCR- and phorbol myristate acetate/ionomycin-induced activation of nuclear factor of activated T cells (NFAT) and T-cell proliferation with an IC₅₀ of ~5 μM. Anti-inflammatory activity.

HY-124603

AT791	Toll-like Receptor (TLR)	Inflammation/Immunology
AT791 is a potent and orally bioavailable TLR7 and TLR9 inhibitor. AT791 inhibits TLR7 and 9 signaling in a variety of human and mouse cell types and inhibits DNA-TLR9 interaction in vitro.

HY-19569A

Upadacitinib tartrate tetrahydrate ABT-494 tartrate tetrahydrate	JAK	Inflammation/Immunology
Upadacitinib (ABT-494) tartrate tetrahydrate is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib tartrate tetrahydrate displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib tartrate tetrahydrate can be used for several autoimmune disorders research.

HY-148104

ACSS2-IN-2	Others	Cancer Infection Metabolic Disease Inflammation/Immunology Neurological Disease
ACSS2-IN-2 is an acyl-CoA synthetase short-chain family member 2 (ACSS2) inhibitor. ACSS2-IN-2 can inhibit ACSS2 activity with an IC₅₀ value of 3.8 nM. ACSS2-IN-2 can be used for the research of several diseases, such as viral infection, metabolic disorders, neuropsychiatric diseases, inflammatory/autoimmune conditions and cancer.

HY-13027

DAPT GSI-IX	γ-secretase Amyloid-β Autophagy Notch Apoptosis	Cancer Inflammation/Immunology Neurological Disease
DAPT (GSI-IX) is a potent and orally active γ-secretase inhibitor with IC₅₀s of 115 nM and 200 nM for total amyloid-β (Aβ) and Aβ₄₂, respectively. DAPT inhibits the activation of Notch 1 signaling and induces cell differentiation. DAPT also induces autophagy and apoptosis. DAPT has neuroprotection activity and has the potential for autoimmune and lymphoproliferative diseases, degenerative disease and cancers treatment.

HY-133747

JAK3-IN-9	JAK	Inflammation/Immunology
JAK3-IN-9 is an orally active JAK3 inhibitor with IC₅₀ value of 1.7 nM. JAK3-IN-9 is highly selective to the JAK3 signal path. JAK3-IN-9 is lowly toxic with high oral bioavailability, shows good anti-arthritis activity. JAK3-IN-9 can be used in *autoimmune* disease research.

HY-135810S

Cletoquine-d4 Desethylhydroxychloroquine-d₄	Influenza Virus Parasite	Infection Inflammation/Immunology
Cletoquine-d₄ is deuterium labeled Cletoquine. Cletoquine (Desethylhydroxychloroquine) is a major active metabolite of Hydroxychloroquine. Cletoquine is produced in the liver by CYP2D6, CYP3A4, CYP3A5, and CYP2C8 isoenzymes. Cletoquine is also a Chloroquine derivative and has the ability to against the chikungunya virus (CHIKV). Cletoquine has antimalarial effects and has the potential for autoimmune diseases treatment[1][2].

HY-112701

CCR6 inhibitor 1	CCR	Cancer Inflammation/Immunology Endocrinology
CCR6 inhibitor 1 is a potent and selective CCR6 inhibitor, with IC₅₀s of 0.45 and 6 nM for monkey and human CCR6, much more selective at CCR6 over human CCR1 (IC₅₀, > 30000 nM), and CCR7 (IC₅₀, 9400 nM). CCR6 inhibitor 1 markedly blocks ERK phosphorylation. CCR6 inhibitor 1 is used in the research of autoimmune diseases and cancer.

HY-B0157

Ketotifen HC 20-511	Endogenous Metabolite Histamine Receptor SARS-CoV Influenza Virus	Infection Endocrinology Inflammation/Immunology
Ketotifen (HC 20-511) is an orally active second-generation noncompetitive histamine 1 (H1) receptor blocker and mast cell stabilizer. Ketotifen can block 6-phosphogluconate dehydrogenase (PGD) in vitro. Ketotifen also has antiviral activity against SARS-CoV-2 and Influenza virus. Ketotifen can be used to the research of autoimmune encephalomyelitis (EAE) and asthma attack prevention.

HY-W181102

NFAT Inhibitor-2	Others	Inflammation/Immunology Neurological Disease Cardiovascular Disease
NFAT Inhibitor-2 is a potent inhibitor of calcineurin NFAT signalling. Calcineurin is a serine/threonine protein phosphatase regulated by Ca2+ and calmodulin. NFAT Inhibitor-2 has the potential for the research of inflammatory disease, an autoimmune disorder, a cardiovascular disease, a neurodegenerative disease, a disease occurring with uncontrolled cell proliferation and/or differentiation, an angiogenesis-related disease, an allergy, anaphylaxis and alopecia (extracted from patent WO2016207212A1, compound 17).

HY-135810S1

Cletoquine-d4-1 Desethylhydroxychloroquine-d₄-1	Influenza Virus Parasite	Infection Inflammation/Immunology
Cletoquine-d₄-1 is the deuterium labeled Cletoquine. Cletoquine (Desethylhydroxychloroquine) is a major active metabolite of Hydroxychloroquine. Cletoquine is produced in the liver by CYP2D6, CYP3A4, CYP3A5, and CYP2C8 isoenzymes. Cletoquine is also a Chloroquine derivative and has the ability to against the chikungunya virus (CHIKV). Cletoquine has antimalarial effects and has the potential for autoimmune diseases treatment[1][2].

HY-B0157A

Ketotifen fumarate HC 20511 fumarate	Histamine Receptor Endogenous Metabolite SARS-CoV Influenza Virus	Inflammation/Immunology Endocrinology Cancer
Ketotifen (HC 20-511) fumarate is an orally active second-generation noncompetitive histamine 1 (H1) receptor blocker and mast cell stabilizer. Ketotifen fumarate can block 6-phosphogluconate dehydrogenase (PGD) in vitro. Ketotifen fumarate also has antiviral activity against SARS-CoV-2 and Influenza virus. Ketotifen fumarate can be used to the research of autoimmune encephalomyelitis (EAE) and asthma attack prevention.

HY-108944

LYP-IN-1	SHP2 Phosphatase	Inflammation/Immunology
LYP-IN-1 is a potent, selective and specific LYP inhibitor with a K_i and an IC₅₀ of 110 nM and 0.259 μM, respectively. LYP-IN-1 also has selectivity for a large panel of PTPs, such as SHP1 (IC₅₀=5 μM) and SHP2 (IC₅₀=2.5 μM). LYP-IN-1 exhibits highly efficacious cellular activity in T- and mast cells. LYP-IN-1 can be used for the study of autoimmune disorders.

HY-129039

Butyrolactone 3 MB-3	Histone Acetyltransferase	Cancer Metabolic Disease Inflammation/Immunology Neurological Disease
Butyrolactone 3 (MB-3) is a specifical small-molecule inhibitor of the histone acetyltransferase Gcn5 (IC₅₀=100 μM), which has a high affinity to the Gcn5 enzyme comparable to that of its natural substrate, histone H3. Butyrolactone 3 shows weak inhibitory on CBP (IC₅₀=0.5 mM). Butyrolactone 3 can be used in studies of cancer, metabolic, autoimmune and neurological diseases.

HY-117433S

4-Hydroperoxy Cyclophosphamide-d4	DNA Alkylator/Crosslinker Apoptosis Reactive Oxygen Species Drug Metabolite	Inflammation/Immunology
4-Hydroperoxy Cyclophosphamide-d₄ is the deuterium labeled 4-Hydroperoxy cyclophosphamide. 4-Hydroperoxy cyclophosphamide is the active metabolite form of the proagent Cyclophosphamide. 4-Hydroperoxy cyclophosphamide crosslinks DNA and induces T cell apoptosis independent of death receptor activation, but activates mitochondrial death pathways through production of reactive oxygen species (ROS). 4-Hydroperoxy cyclophosphamide has the potential for lymphomas and autoimmune disorders[1][2].

HY-120214

TAS05567	Syk RET	Inflammation/Immunology
TAS05567 is a potent, highly selective, ATP-competitive and orally active Syk inhibitor with an IC₅₀ of 0.37 nM. In a panel of 192 kinases, TAS05567 only shows >70% inhibition of Syk and 4 other kinases (FLT3, JAK2, KDR and RET with IC₅₀s of 10 nM, 4.8 nM, 600 nM and 29 nM, respectively). TAS05567 can be used for humoral immune-mediated inflammatory conditions such as autoimmune and allergic diseases.

HY-101762

TyK2-IN-2	JAK Phosphodiesterase (PDE)	Inflammation/Immunology
TyK2-IN-2 (Compoud 18) is a potent and selective TYK2 inhibitor with IC₅₀s of 7 nM, 0.1 μM and 0.05 μM for TYK2 JH2, IL-23 and IFNα, respectively. TyK2-IN-2 also inhibits phosphodiesterase 4 (PDE4) with an IC₅₀ of 62 nM. TyK2-IN-2 can be used for the research of inflammatory and autoimmune diseases.

HY-100891

CD80-IN-3
CD28 Inflammation/Immunology

CD80-IN-3, a potent CD80 inhibitor, inhibits CD80/CD28 interaction with an EC₅₀ of 630 nM and a K_d of 125 nM.

HY-151108

IDO1/TDO-IN-4	Indoleamine 2,3-Dioxygenase (IDO)	Inflammation/Immunology Neurological Disease
IDO1/TDO-IN-4 is a potent IDO1/TDO dual inhibitor, with IC₅₀ values of 3.53 μM (IDO1) and 1.15 μM (TDO). IDO1/TDO-IN-4 forms hydrogen bond with IDO1, and π−π stacking interaction with TDO. IDO1/TDO-IN-4 can be used in the research of depression, and depression-induced infectious, metabolic, and autoimmune disorders.

HY-120978

Omega-3 arachidonic acid methyl ester ω-3 Arachidonic acid methyl ester; (all-Z)-8,11,14,17-Eicosatetraenoic acid methyl ester	Biochemical Assay Reagents	Others
omega-3 Arachidonic Acid methyl ester, mainly represented by docosahexaenoic acid, eicosapentaenoic acid and alpha-linoleic acid, are essential dietary nutrients required for normal growth and development. Methyl omega-3 arachidonic acid is a neutral fat-soluble form of the rare fatty acid omega-3 arachidonic acid. Omega-3 fatty acids, as a group, have been associated with reduced inflammation and autoimmune activity, as well as reduced thrombosis and platelet activation.

HY-145933

BJJF078	Glutaminase	Inflammation/Immunology
BJJF078 is an aminopiperidine derivative. BJJF078 is a potent inhibitor of recombinant human and mouse Transglutaminase enzyme (TG2) activity, IC₅₀ values of 41 and 54 nM, respectively. BJJF078 also inhibits the close related enzyme TG1, with an IC₅₀ of 0.16 μM. BJJF078 can be used for Multiple sclerosis (MS) research.

HY-147642

ChemR23-IN-4
Others Inflammation/Immunology

ChemR23-IN-4 (Compound 13) is a potent and orally efficacious ChemR23 inhibitor with an IC₅₀ of 17 nM against human ChemR23.

HY-133122

UCB-9260	TNF Receptor	Inflammation/Immunology
UCB-9260, an orally active compound, inhibits TNF signaling by stabilising an asymmetric form of the trimer. UCB-9260 is selective for TNF over other superfamily members, and binds TNF with a similar K_d of 13 nM.

HY-110132

JNJ-27141491
CCR Inflammation/Immunology

JNJ-27141491 is a selective, noncompetitive and orally active functional antagonist of human CCR2.

HY-143884

JAK2/TYK2-IN-1	JAK	Inflammation/Immunology
JAK2/TYK2-IN-2 is a potent and selective TYK2 inhibitor with IC₅₀ values of 9 and 157 nM for TYK2 and JAK2, respectively. JAK2/TYK2-IN-2 has anti-inflammatory activity.

HY-B0352

Mirtazapine Org3770; 6-Azamianserin	5-HT Receptor Histamine Receptor Adrenergic Receptor	Inflammation/Immunology Neurological Disease Cancer
Mirtazapine (Org3770) is a potent and orally active noradrenergic and specific serotonergic antidepressant (NaSSA) agent. Mirtazapine is also a 5-HT₂, 5-HT₃, histamine H1 receptor and α2-adrenoceptor antagonist with pK_i values of 8.05, 8.1, 9.3 and 6.95, respectively.

HY-142677

PI3K-IN-27	PI3K	Cancer Inflammation/Immunology
PI3K-IN-27 is a potent inhibitor of PI3K. PI3K belongs to a large family of lipid signaling kinase that plays key role in cellular process including cell growth, differentiation, migration and apoptosis. PI3K-IN-27 has the potential for the research of hyper-proliferative diseases like cancer and inflammation, or immune and autoimmune diseases (extracted from patent WO2021233227A1, compound 1).

HY-150751

ODN TTAGGG ODN A151	Toll-like Receptor (TLR) AIM2	Inflammation/Immunology
ODN TTAGGG (A151), inhibitory oligonucleotide (ODN), is a TLR9, AIM2 and cGAS antagonist. ODN TTAGGG is immunosuppressive and inhibits AIM2 inflammasome activation, as well as cGAS activation, by competing with DNA. ODN TTAGGG can be used in the study of lupus erythematosus and other related autoimmune diseases. ODN TTAGGG sequence: 5'-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-3'.

HY-10405S

Pamapimod-d4	p38 MAPK Autophagy	Inflammation/Immunology
Pamapimod-d₄ (Ro4402257-d4) is the deuterium labeled Pamapimod. Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC50s of 14 nM and 480 nM and Kis of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment[1][2].

HY-142949

ALK5-IN-7	TGF-β Receptor	Cancer Inflammation/Immunology
ALK5-IN-7 is a potent inhibitor of ALK5. Transforming growth factor beta (TGF-β) is a multifunctional cytokine that is involved in regulating cell proliferation, differentiation and apoptosis through complex receptor signaling pathways on the cell surface in an autocrine, paracrine and endocrine manner. ALK5-IN-7 has the potential for the research of TGF-β-related diseases and conditions, including but not limited to tumors, fibrotic diseases, inflammatory diseases, autoimmune diseases, etc (extracted from patent WO2021129621A1, compound 4).

HY-108601A

Ro 32-0432 hydrochloride	PKC	Inflammation/Immunology Neurological Disease
Ro 32-0432 hydrochloride is a potent, selective, ATP-competitive and orally active PKC inhibitor. The IC₅₀ values of Ro 32-0432 hydrochloride for PKCα, PKCβI, PKCβII, PKCγ and PKCε are 9.3 nM, 28 nM, 30 nM, 36.5 nM and 108.3 nM, respectively. Ro 32-0432 hydrochloride is also a selective G protein-coupled receptor kinase 5 (GRK5) inhibitor. Ro 32-0432 hydrochloride prevents T-cell activation and has the potential for chronic inflammatory and autoimmune diseases research.

HY-117287

Deucravacitinib BMS-986165	JAK Interleukin Related IFNAR	Inflammation/Immunology
Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC₅₀=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis.

HY-142950

ALK5-IN-6	TGF-β Receptor	Cancer Inflammation/Immunology
ALK5-IN-6 is a potent inhibitor of ALK5. Transforming growth factor beta (TGF-β) is a multifunctional cytokine that is involved in regulating cell proliferation, differentiation and apoptosis through complex receptor signaling pathways on the cell surface in an autocrine, paracrine and endocrine manner. ALK5-IN-6 has the potential for the research of TGF-β-related diseases and conditions, including but not limited to tumors, fibrotic diseases, inflammatory diseases, autoimmune diseases, etc (extracted from patent WO2021129621A1, compound 1).

HY-145771

PD-1/PD-L1-IN-20	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-20 (Example 21) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-20 blocks PD-1/PD-L1 with the IC₅₀ of 5.29 nM. PD-1/PD-L1-IN-20 can be used for the research of cancers, infectious diseases and autoimmune diseases.

HY-145770

PD-1/PD-L1-IN-19	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-19 (Example 22) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-19 blocks PD-1/PD-L1 with the IC₅₀ of 62.3 nM. PD-1/PD-L1-IN-19 can be used for the research of cancers, infectious diseases and autoimmune diseases.

HY-145429

IL-17A modulator-2	Interleukin Related	Cancer Inflammation/Immunology Neurological Disease
IL-17A modulator-2 is a IL-17A modulator, extracted from patent WO2021239743+A1, example 27. IL-17A modulator-2 inhibits the biological action of IL-17A with a pIC₅₀ of 8.3. IL-17A modulator-2 can be used for the research of diseases or disorders associated with modulation of IL-17A activity including diseases with an immune component or autoimmune pathol, cancer and neurodegenerative disorders.

HY-145772

PD-1/PD-L1-IN-21	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-21 (Example 22) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-21 blocks PD-1/PD-L1 with the IC₅₀ of 4.99 μM. PD-1/PD-L1-IN-21 can be used for the research of cancers, infectious diseases and autoimmune diseases.

HY-145773

PD-1/PD-L1-IN-22	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-22 (Example 2) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-22 blocks PD-1/PD-L1 with the IC₅₀ of 0.732 μM. PD-1/PD-L1-IN-22 can be used for the research of cancers, infectious diseases and autoimmune diseases.

HY-110100

CPYPP	Others	Inflammation/Immunology
CPYPP is a DOCK2-Rac1 interaction inhibitor. CPYPP binds to DOCK2 DHR-2 domain and inhibits the guanine nucleotide exchange factor (GEF) activity of DOCK2^DHR-2 for Rac1 in a dose-dependent manner with an IC₅₀ of 22.8 µM. CPYPP also inhibits DOCK180 and DOCK5 and less inhibits DOCK9.

HY-125139

omega-3 Arachidonic acid ethyl ester ω-3 Arachidonic acid ethyl ester; (all-Z)-8,11,14,17-Eicosatetraenoic acid ethyl ester	Biochemical Assay Reagents	Others
omega-3 Arachidonic Acid ethyl ester is a rare polyunsaturated fatty acid found in very small amounts in dietary sources. Omega-3 fatty acids are known to be essential for the growth and development of infants, and they protect against heart disease, blood clots, high blood pressure, and inflammatory and autoimmune diseases. In human platelet membranes, omega-3 arachidonic acid inhibits arachidonyl-CoA synthetase with a Ki of 14 μM. It also inhibits arachidonoyl-CoA synthetase in calf brain extract with an IC50 of approximately 5 μM. Omega-3 ethyl arachidonate is the more lipophilic form of the free acid.

HY-109520

Glatiramer acetate	Others	Inflammation/Immunology
Glatiramer acetate, a synthetic analogue of myelin basic protein and an immunomodulating agent, can be used for the research of multiple sclerosis. Glatiramer acetate exhibits strong and promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. A further aspect of its action is potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression.

HY-P1571

Nucleoprotein (396-404) NP 396	Arenavirus	Inflammation/Immunology
Nucleoprotein (396-404) is the 396 to 404 fragment of lymphocytic choriomeningitis virus (LCMV). Nucleoprotein (396-404) is the H-2D(b)-restricted immunodominant epitope and can be used as a molecular model of viral antigen .

HY-P1571A

Nucleoprotein (396-404) (TFA) NP 396 TFA	Arenavirus	Inflammation/Immunology
Nucleoprotein (396-404) TFA is the 396 to 404 fragment of lymphocytic choriomeningitis virus (LCMV). Nucleoprotein (396-404) TFA is the H-2D(b)-restricted immunodominant epitope and can be used as a molecular model of viral antigen .

HY-12345

ML365	Potassium Channel	Cardiovascular Disease
ML365 is a selective two-pore domain potassium channel KCNK3/TASK1 inhibitor, with an IC₅₀ of 4 nM. ML365 acts as a pharmacological tool that can be used to examine the specific roles of TASK1 channels.

HY-144126

S1P1 agonist 5	LPL Receptor	Inflammation/Immunology
S1P1 agonist 5 is a selective and orally active S1P1 agonist. S1P1 agonist 5 inhibits the lymphocyte egress from the lymphoid tissue to the peripheral blood. S1P1 agonist 5 has the potential for the research of multiple sclerosis (MS).

HY-116018

FKGK11	Phospholipase	Cancer Inflammation/Immunology Neurological Disease
FKGK11 is a potent and selective inhibitor of GVIA iPLA2 (Group VIA calcium-independent phospholipase A2). FKGK11 can be used for the research of ovarian cancer and neurological disorders such as peripheral nerve injury and multiple sclerosis.

HY-147660

IMMH001	LPL Receptor	Inflammation/Immunology
IMMH001, also called SYL930, is an orally active, potent and selective S1P1 (sphingosine-1-phosphate receptor 1) agonist. IMMH001 decreased levels of both chemokines and proinflammatory cytokines, including IL-1β, IL-5, IL-18, IP10, CCL3, and CCL5. IMMH001 can be used for rheumatoid arthritis (RA) research.

HY-149004

SLF1081851
LPL Receptor Inflammation/Immunology

SLF1081851 is a Spns2 inhibitor, inhibits S1P release (IC₅₀=1.93 μM). SLF1081851 plays a key role in development and immune system.

HY-134911

HS-243	IRAK CDK	Cancer Inflammation/Immunology
HS-243 is a potent and selective IRAK-4 and IRAK-1 inhibitor, with IC₅₀ values of 20 and 24 nM. HS-243 shows minimal TAK1 (transforming growth factor β-activated kinase 1) inhibition activity, with a IC₅₀ of 0.5 μM. HS-243 shows anti-inflammatory and anticancer activity.

HY-151093

IDO2-IN-1	Indoleamine 2,3-Dioxygenase (IDO)	Inflammation/Immunology
IDO2-IN-1 is an orally active and potent Indoleamine 2,3-dioxygenase 2 (IDO2) inhibitor with an IC₅₀ value of 112 nM. IDO2-IN-1 can be used for inflammatory autoimmunity research.

Cat. No.	Product Name

HY-L007

Immunology/Inflammation Compound Library

4232 compounds

The immune system is a host defense system comprising many biological structures and processes within an organism that protects against disease. To function properly, an immune system must detect a wide variety of agents, known as pathogens, from viruses to parasitic worms, and distinguish them from the organism's own healthy tissue. Inflammation is also the body's attempt at self-protection to remove harmful stimuli and begin the healing process. It’s part of the body's immune response. The immune system recognizes damaged cells, irritants, and pathogens, and inflammation begins the healing process. Inflammatory abnormalities are a large group of disorders that underlie a vast variety of human diseases. The immune system is often involved with inflammatory disorders, demonstrated in both allergic reactions and some myopathies, with many immune system disorders resulting in abnormal inflammation.

MCE designs a unique collection of 4232 compounds that are useful tool for Immunology/Inflammation research or autoimmune inflammatory diseases drug discovery.

HY-L024

Histone Modification Research Compound Library

521 compounds

A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases.

MCE owns a unique collection of 521 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.

HY-L014

NF-κB Signaling Compound Library

672 compounds

Nuclear factor-κB (NF-κB)/Rel proteins include NF-κB2 p52/p100, NF-κB1 p50/p105, c-Rel, RelA/p65, and RelB. These proteins function as dimeric transcription factors that regulate the expression of genes and influence a broad range of biological processes including innate and adaptive immunity, inflammation, stress responses, B-cell development, and lymphoid organogenesis. NF-κB plays a key role in regulating the immune response to infection. In addition, activation of the NF-κB pathway is involved in the pathogenesis of chronic inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development.

MCE owns a unique collection of 672 small molecule compounds that can be used in the research of NF-κB signaling pathway or high throughput screening (HTS) related drug discovery.

Cat. No.	Product Name	Type

HY-120978

Omega-3 arachidonic acid methyl ester

ω-3 Arachidonic acid methyl ester; (all-Z)-8,11,14,17-Eicosatetraenoic acid methyl ester

Biochemical Assay Reagents

omega-3 Arachidonic Acid methyl ester, mainly represented by docosahexaenoic acid, eicosapentaenoic acid and alpha-linoleic acid, are essential dietary nutrients required for normal growth and development. Methyl omega-3 arachidonic acid is a neutral fat-soluble form of the rare fatty acid omega-3 arachidonic acid. Omega-3 fatty acids, as a group, have been associated with reduced inflammation and autoimmune activity, as well as reduced thrombosis and platelet activation.

HY-125139

omega-3 Arachidonic acid ethyl ester

ω-3 Arachidonic acid ethyl ester; (all-Z)-8,11,14,17-Eicosatetraenoic acid ethyl ester

Biochemical Assay Reagents

omega-3 Arachidonic Acid ethyl ester is a rare polyunsaturated fatty acid found in very small amounts in dietary sources. Omega-3 fatty acids are known to be essential for the growth and development of infants, and they protect against heart disease, blood clots, high blood pressure, and inflammatory and autoimmune diseases. In human platelet membranes, omega-3 arachidonic acid inhibits arachidonyl-CoA synthetase with a Ki of 14 μM. It also inhibits arachidonoyl-CoA synthetase in calf brain extract with an IC50 of approximately 5 μM. Omega-3 ethyl arachidonate is the more lipophilic form of the free acid.

Cat. No.	Product Name	Target	Research Area

HY-P1587

IRBP (1-20), human	Peptides	Inflammation/Immunology
IRBP (1-20), human contains a major epitope for the H-2^b haplotype. IRBP (1-20), human induces experimental autoimmune uveoretinitis (EAU) in H-2^b mice.

HY-P1587A

IRBP (1-20), human TFA	Peptides	Inflammation/Immunology
IRBP (1-20), human TFA contains a major epitope for the H-2^b haplotype. IRBP (1-20), human TFA induces experimental autoimmune uveoretinitis (EAU) in H-2^b mice.

HY-P3073

Myelin Basic Protein (1-11)	Peptides	Inflammation/Immunology
Myelin Basic Protein (1-11) is an encephalitogenic epitope of myelin basic protein (MBP). Myelin Basic Protein (1-11) can be used for induction of experimental autoimmune encephalomyelitis (EAE).

HY-12523

Peptide M	Peptides	Others
Peptide M is a synthetic amino acid (18 amino acids in length which correspond to the amino acid positions 303-322 of bovine S-antigen: DTNLASSTIIKEGIDKTV), is capable of inducing experimental autoimmune uveitis in monkeys and Hartley guinea pigs as well as Lewis rats.

HY-P2464A

Myosin H Chain Fragment, mouse acetate salt	Peptides	Cardiovascular Disease
Myosin H Chain Fragment, mouse acetate salt is a fragment of the α-Myosin heavy chain peptide. Myosin H Chain Fragment can be used to induce experimental autoimmune myocarditis (EAM) mouse model.

HY-P2464

Myosin H Chain Fragment, mouse	Peptides	Inflammation/Immunology
Myosin H Chain Fragment, mouse is a fragment of the α-Myosin heavy chain peptide. Myosin H Chain Fragment can be used to induce experimental autoimmune myocarditis (EAM) mouse model.

HY-P3719

MOG peptide (35-55)	Peptides	Inflammation/Immunology
MOG peptide (35-55) is a fragment 35-55 of myelin oligodendrocyte glycoprotein (MOG) immunogenic peptide. MOG peptide (35-55) is specific to expanded CD4⁺ T cells, and induces experimental autoimmune encephalomyelitis (EAE) in animal model.

HY-P3986

HUN-7293	Peptides	Inflammation/Immunology
HUN-7293 is a cell adhesion molecule inhibitor. HUN-7293 selectively inhibits the expression of three cell adhesion molecules (VCAM-1, ICAM-1 and E-selectin) (IC₅₀=1-24 nM). HUN-7293 can be used in the study of inflammatory and autoimmune diseases characterized by overexpression of cell adhesion molecules.

HY-P3541

Dirucotide MBP8298	Peptides	Inflammation/Immunology Neurological Disease
Dirucotide (MBP8298) is a synthetic peptide that consists of 17 amino acids linked in a sequence identical to that of a portion of human myelin basic protein. Dirucotide can be used for the research in autoimmune disorder of the central nervous system, such as Multiple sclerosis (MS).

HY-P3817

Des-[Gly77,His78] Myelin Basic Protein (68-84), bovine	Peptides	Neurological Disease
Des-[Gly77,His78] Myelin Basic Protein (68-84) is a 68-84 sequence fragment of guinea pig myelin basic protein (GPMBP). Des-[Gly77,His78] Myelin Basic Protein (68-84) regulates functionally diverse encephalitogenic and proliferative activities of experimental autoimmune encephalomyelitis (EAE)-associated T cells.

HY-105037

Forigerimod IPP-201101	Autophagy	Inflammation/Immunology
Forigerimod (IPP-201101) is a CD4 T-cell modulator. Forigerimod is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .

HY-P4040

Ac-D-DGla-LI-Cha-C	HCV Protease	Cancer Infection Metabolic Disease Inflammation/Immunology Neurological Disease
Ac-D-DGla-LI-Cha-C is a potent HCV protease inhibitor peptide. Ac-D-DGla-LI-Cha-C can be used for the research of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases.

HY-105037A

Forigerimod TFA IPP-201101 TFA	Autophagy	Inflammation/Immunology
Forigerimod TFA (IPP-201101 TFA) is a CD4 T-cell modulator. Forigerimod TFA is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod TFA can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .

HY-P0129

PLP (139-151)	Peptides	Inflammation/Immunology
PLP (139-151) is amino acid residue 139 to 151 of myelin proteolipid protein (PLP) used to induce experimental autoimmune encephalomyelitis (EAE).

HY-P2476

Peripheral Myelin P0 Protein (180-199), mouse	Peptides	Inflammation/Immunology Neurological Disease
Peripheral Myelin P0 Protein (180-199), mouse, a neuritogenic peptide, is a purified component of murine peripheral nerve myelin.

HY-P3446A

Big Gastrin I (human) (TFA)	Peptides	Cancer Infection Inflammation/Immunology Neurological Disease Cardiovascular Disease
Big Gastrin I, human (TFA) is a gastrointestinal hormone consisting of 34 amino acids. Big Gastrin I, human (TFA) can be used as a potential substance for the study of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurological diseases or cardiovascular diseases.

HY-P1745

InsB (9-23) Insulin B chain (9-23)	Peptides	Inflammation/Immunology
InsB (9-23) is an insulin B-chain peptide that binds to a class II histocompatibility complex (MHC) allele called I-Ag7. InsB (9-23) can be used to treat a number of autoimmune related diseases like Type 1 diabetes.

HY-P3507

Dalazatide ShK-186	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease.

HY-P3507A

Dalazatide TFA ShK-186 TFA	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease.

HY-P2479

Peripheral Myelin Protein P2 (53-78), bovine	Peptides	Inflammation/Immunology
Peripheral Myelin Protein P2 (53-78), bovine is derived from bovine peripheral myelin P2 protein amino acid residues 53-78. Peripheral Myelin Protein P2 (53-78), bovine is a T cell epitope for the induction of experimental autoimmune neuritis (EAN) in Lewis rats.

HY-P5121A

γ-Fibrinogen 377-395 TFA	Peptides	Cardiovascular Disease
γ-Fibrinogen377-395 TFA is a fibrinogen-derived inhibitory peptide, as well as fibrinogen epitope. γ-Fibrinogen377-395 TFA blocks microglia activation and inhibits fibrin-Mac-1 interactions in vitro, and suppresses experimental autoimmune encephalomyelitis (EAE) in mice in vivo. γ-Fibrinogen377-395 TFA can be used for research in multiple sclerosis (MS), and other neuroinflammatory diseases associated with blood-brain barrier disruption and microglia activation.

HY-P5121

γ-Fibrinogen 377-395	Peptides	Cardiovascular Disease
γ-Fibrinogen377-395 is a fibrinogen-derived inhibitory peptide, as well as fibrinogen epitope. γ-Fibrinogen377-395 blocks microglia activation and inhibits fibrin-Mac-1 interactions in vitro, and suppresses experimental autoimmune encephalomyelitis (EAE) in mice in vivo. γ-Fibrinogen377-395 can be used for research in multiple sclerosis (MS), and other neuroinflammatory diseases associated with blood-brain barrier disruption and microglia activation.

HY-P2459

MOG (35-55), human	Peptides	Neurological Disease
MOG (35-55), human is a component of CNS myelin. MOG (35-55), human is different from mMOG (35-55) by a proline for serine substitution at position 42. MOG (35-55), human is also immunogenic, but not encephalitogenic, and is only partially cross-reactive with mMOG35–55. MOG (35-55), human induces minimal clinical signs of EAE relative to the rodent peptide.

HY-143884

JAK2/TYK2-IN-1	JAK	Inflammation/Immunology
JAK2/TYK2-IN-2 is a potent and selective TYK2 inhibitor with IC₅₀ values of 9 and 157 nM for TYK2 and JAK2, respectively. JAK2/TYK2-IN-2 has anti-inflammatory activity.

HY-P1571

Nucleoprotein (396-404) NP 396	Arenavirus	Inflammation/Immunology
Nucleoprotein (396-404) is the 396 to 404 fragment of lymphocytic choriomeningitis virus (LCMV). Nucleoprotein (396-404) is the H-2D(b)-restricted immunodominant epitope and can be used as a molecular model of viral antigen .

HY-P1571A

Nucleoprotein (396-404) (TFA) NP 396 TFA	Arenavirus	Inflammation/Immunology
Nucleoprotein (396-404) TFA is the 396 to 404 fragment of lymphocytic choriomeningitis virus (LCMV). Nucleoprotein (396-404) TFA is the H-2D(b)-restricted immunodominant epitope and can be used as a molecular model of viral antigen .

Cat. No.	Product Name	Target	Research Area

HY-P99761

Obexelimab XmAb5871	Inhibitory Antibodies	Inflammation/Immunology
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody Fc-engineered for increased affinity to FcγRIIb. Obexelimab can be used in research of autoimmune.

HY-P99529

Valziflocept BAX1810; TAK-752	Inhibitory Antibodies	Inflammation/Immunology
Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind and neutralize pathogenic IgG, thus forming a "decoy" or "scavenger" receptor that can reduce the severity of autoimmune diseases. Valziflocept can be used in studies of autoimmune diseases such as systemic lupus erythematosus (SLE).

HY-P99570

Telazorlimab GBR-830	Inhibitory Antibodies	Inflammation/Immunology
Telazorlimab (GBR-830) is a humanized monoclonal antibody against OX40 costimulatory receptor on activated T cells. Telazorlimab can be used for the research of autoimmune diseases.

HY-P99327

Tregalizumab BT-061	Inhibitory Antibodies	Inflammation/Immunology
Tregalizumab is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. Tregalizumab can be used in the research of autoimmune diseases (resulting from insufficient Treg activity) and allergies.

HY-P99568

Telitacicept RC18	Inhibitory Antibodies	Inflammation/Immunology
Telitacicept (RC18) is a fully human TACI-Fc fusion protein. Telitacicept is a dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. Telitacicept can be used in research of B-cell autoimmune disease.

HY-P99563

Tibulizumab LY 3090106; LY-3090106; LY3090106	TNF Receptor Interleukin Related	Inflammation/Immunology
Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research.

HY-P99173

MDX-1342	Inhibitory Antibodies	Cancer
MDX-1342 is a fully human monoclonal antibody (HuMAb) of targeting CD19-membrane receptor. MDX-1342 can specifically bind to human CD19 antigen with high affinity and has antibody-dependent cellular cytotoxicity (ADCC) effect. MDX-1342 can be used for the research of B-lymphocyte malignancies and autoimmune.

HY-P9970

Infliximab Avakine; CT-P13	TNF Receptor Bacterial	Metabolic Disease Inflammation/Immunology Neurological Disease Cancer
Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research.

HY-P99446

Atacicept TACI-Ig; TACI-Fc 5	Inhibitory Antibodies	Inflammation/Immunology
Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease.

HY-108810

Canakinumab Ilaris; ACZ 885	Interleukin Related	Inflammation/Immunology
Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC₅₀ values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin.

HY-P99459

Baminercept BG 9924; TT-47	Inhibitory Antibodies	Inflammation/Immunology
Baminercept (BG 9924) is a lymphotoxin β receptor IgG fusion protein (LTβR-Ig). Baminercept can be used for the research of many autoimmune diseases including primary Sjögren's syndrome (SS) and rheumatoid arthritis (RA) .

HY-P99220

Tabalumab LY2127399	TNF Receptor	Inflammation/Immunology
Tabalumab (LY2127399) is a humanised anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus.

HY-P99190

Eldelumab BMS-936557; MDX-1100	CXCR	Inflammation/Immunology
Eldelumab (BMS-936557) is a humanised anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease.

HY-P9913

Rituximab Anti-Human CD20 type I, Chimeric Antibody	CD20	Cancer Inflammation/Immunology
Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.

HY-P99009

Batoclimab HBM9161; IMVT-1401	Inhibitory Antibodies	Inflammation/Immunology
Batoclimab is a human anti-FcRn monoclonal antibody. Batoclimab can be used for the research of autoimmune diseases mediated by pathogenic IgG antibodies.

HY-P9913A

Rituximab (anti-CD20)	CD20	Cancer Inflammation/Immunology
Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer.

HY-P99310

Perakizumab RG4934; Anti-Human IL17A Recombinant Antibody	Interleukin Related	Inflammation/Immunology
Perakizumab (RG4934) is a humanized IgG1κ monoclonal antibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis.

HY-P99670

Iscalimab CFZ-533; OM11-62MF	TNF Receptor	Metabolic Disease Inflammation/Immunology
Iscalimab (CFZ-533) is a non-depleting IGg1 monoclonal antibody targeting CD40 (K_D: 0.3 nM). Iscalimab can be used for research of Graves' hyperthyroidism and autoimmune diseases.

HY-P9979

Rozanolixizumab UCB7665	Inhibitory Antibodies	Inflammation/Immunology
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases.

HY-P99728

Melredableukin alfa RG7835; RO7049665	Interleukin Related	Inflammation/Immunology
Melredableukin alfa (RO-7049665) is a fusion protein that consists of a human IgG1-κ fused to a mutated human interleukin 2 (IL2 mutein) via a peptide linker. Melredableukin alfa can be used for the research of autoimmune hepatitis and ulcerative colitis.

HY-P99793

Orticumab MLDL1278A	LDLR	Inflammation/Immunology
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement.

HY-P99289

Epratuzumab Antibody hLL 2; Anti-Human CD22 Recombinant Antibody	CD22	Cancer Inflammation/Immunology
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases.

HY-P99335

Vunakizumab Anti-Human IL17A Recombinant Antibody	Interleukin Related	Inflammation/Immunology
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis.

HY-108829

Abatacept CTLA4lg; BMS-188667	CTLA-4	Inflammation/Immunology Cancer
Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases.

HY-P99385

Vobarilizumab ALX-0061	Interleukin Related	Inflammation/Immunology
Vobarilizumab (ALX-0061) is an anti-IL-6R monoclonal antibody (mAb) (K_d: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis.

HY-145771

PD-1/PD-L1-IN-20	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-20 (Example 21) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-20 blocks PD-1/PD-L1 with the IC₅₀ of 5.29 nM. PD-1/PD-L1-IN-20 can be used for the research of cancers, infectious diseases and autoimmune diseases.

Cat. No.	Product Name	Target	Category

HY-N3103

p-Coumaric Acid Ethyl Ester Ethyl (E)-p-hydroxycinnamate; Ethyl trans-4-hydroxycinnamate	Drug Metabolite	Phenylpropanoids Simple Phenylpropanols Phenols Monophenols Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Plants other families
p-Coumaric Acid Ethyl Ester is the ethyl ester of p-Coumaric acid. p-Coumaric Acid is a potential immunosuppressive agent in treating autoimmune inflammatory diseases like rheumatoid arthritis.

HY-N8441

Neriifolin 17β-Neriifolin	Na+/K+ ATPase Apoptosis	Steroids Cardiacglycosides Inflammation/Immunology Disease Research Fields Classification of Application Fields Source classification Plants Apocynaceae Cerbera manghas Linn.
Neriifolin, a CNS-penetrating cardiac glycoside, is an inhibitor of the Na⁺, K⁺-ATPase. Neriifolin can target beclin 1, inhibits the formation of LC3-associated phagosomes and ameliorates experimental autoimmune encephalomyelitis (EAE) development. Neriifolin induces cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells^[2.

HY-N10768

1-Dehydro-[10]-gingerdione	IKK NF-κB	Structural Classification Monophenols Phenols Plants Source classification Zingiberaceae
1-Dehydro-[10]-gingerdione directly inhibits IKKβ activity by targeting the activation loop of IKKβ, thus disrupting IKKβ-catalysed IκBα phosphorylation in macrophages stimulated with agonists. 1-Dehydro-[10]-gingerdione inhibits LPS (HY-D1056)-induced NF-κB transcriptional activity. 1-Dehydro-[10]-gingerdione has the potential for NF-κB-associated inflammation and autoimmune disorders research.

HY-N2335

Coumestrol	Estrogen Receptor/ERR	Coumarins Phenylpropanoids Phenols Polyphenols Disease Research Fields Cancer Classification of Application Fields Source classification Plants Leguminosae Glycine max (L.) merr
Coumestrol, a phytoestrogen present in soybean products, exhibits activities against cancers, neurological disorders, and autoimmune diseases. It suppresses proliferation of ES2 cells with an IC₅₀ of 50 μM.

HY-N10520

Pectic acid Methyl protopectin; Polygalacturonic acid	Apoptosis Necroptosis Endogenous Metabolite	Saccharides Polysaccharides Structural Classification Natural Products Rutaceae Citrus reticulata Blanco Plants Inflammation/Immunology Disease Research Fields Cancer Classification of Application Fields
Pectic acid (Methyl protopectin), a polygalacturonic acid, induces cell apoptosis and necrosis in pituitary tumor cells. Pectic acid can be used in the research of cancers and autoimmune disease.

HY-N7703

D-Mannuronic acid sodium	Others	Saccharides Monosaccharides Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Plants other families
D-Mannuronic acid sodium, isolated from Macrocystis pyrifera, has the potential in autoimmune encephalomyelitis (EAE), adjuvant induced arthritis (AIA), nephrotic syndrome, and acute glomerulonephritis studies.

HY-N2279

Kurarinone	Others	Flavonoids Flavonones Phenols Polyphenols Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Plants Leguminosae Sophora flavescens
Kurarinone, a flavanoid derived from shrub Sophora flavescens, inhibits the process of experimental autoimmune encephalomyelitis via blocking Th1 and Th17 cell differentiation.

HY-N11451

Lacto-N-fucopentaose III LNFP-III	Arginase Aldehyde Dehydrogenase (ALDH) Indoleamine 2,3-Dioxygenase (IDO)	Saccharides Polysaccharides Structural Classification Animals Source classification
Lacto-N-fucopentaose III (LNFP-III) is an immune modulator. Lacto-N-fucopentaose III reduces the severity of experimental autoimmune encephalomyelitis (EAE) and CNS inflammation.

HY-114495

Caerulomycin A Cerulomycin; Caerulomycin	Fungal Antibiotic	Antibiotics Structural Classification Other Antibiotics Microorganisms Source classification Inflammation/Immunology Disease Research Fields Classification of Application Fields
Caerulomycin A (Cerulomycin; Caerulomycin), an antifungal compound, induces generation of T cells, enhances TGF-β-Smad3 protein signaling via suppressing interferon-γ-induced STAT1 signaling. Antifungal and antibiotic activity, and used in autoimmune diseases.

Cat. No.	Product Name

HY-144031S

Tyk2-IN-8
Tyk2-IN-8 is a selective Tyk-2 inhibitor with an IC50 of 5.7 nM for TYK2-JH2. Tyk2-IN-8 inhibits JAK1-JH1 with IC50 of 3.0 nM. Tyk2-IN-8 can be used for the research of autoimmune disease[1].

HY-50856S

Deuruxolitinib
Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), modulates the activity of JAK1/JAK2. Deuruxolitinib can be used for the research hair loss disorders (from patent WO2017192905A1, compound I).

HY-135810S

Cletoquine-d4

Cletoquine-d₄ is deuterium labeled Cletoquine. Cletoquine (Desethylhydroxychloroquine) is a major active metabolite of Hydroxychloroquine. Cletoquine is produced in the liver by CYP2D6, CYP3A4, CYP3A5, and CYP2C8 isoenzymes. Cletoquine is also a Chloroquine derivative and has the ability to against the chikungunya virus (CHIKV). Cletoquine has antimalarial effects and has the potential for autoimmune diseases treatment[1][2].

HY-135810S1

Cletoquine-d4-1

Cletoquine-d₄-1 is the deuterium labeled Cletoquine. Cletoquine (Desethylhydroxychloroquine) is a major active metabolite of Hydroxychloroquine. Cletoquine is produced in the liver by CYP2D6, CYP3A4, CYP3A5, and CYP2C8 isoenzymes. Cletoquine is also a Chloroquine derivative and has the ability to against the chikungunya virus (CHIKV). Cletoquine has antimalarial effects and has the potential for autoimmune diseases treatment[1][2].

HY-117433S

4-Hydroperoxy Cyclophosphamide-d4

4-Hydroperoxy Cyclophosphamide-d₄ is the deuterium labeled 4-Hydroperoxy cyclophosphamide. 4-Hydroperoxy cyclophosphamide is the active metabolite form of the proagent Cyclophosphamide. 4-Hydroperoxy cyclophosphamide crosslinks DNA and induces T cell apoptosis independent of death receptor activation, but activates mitochondrial death pathways through production of reactive oxygen species (ROS). 4-Hydroperoxy cyclophosphamide has the potential for lymphomas and autoimmune disorders[1][2].

HY-10405S

Pamapimod-d4

Pamapimod-d₄ (Ro4402257-d4) is the deuterium labeled Pamapimod. Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC50s of 14 nM and 480 nM and Kis of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment[1][2].

autoimmune

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products